Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
37.8 /100
Rank 16 out of 27 Sectors -
Advance/Decline
324/322
-
No. of Companies646
-
Avg. Market Cap8,654
-
Price to Earning Ratio6.01
-
Price to Earning Growth Ratio0.93
-
Price to Book Ratio24.36
-
Return on Equity15.67
-
Return on Capital Employed-
-
Return on Assets5.34
-
Dividend yield 1 year %0.64 %
-
Net Profit Growth Annual YoY %46.07 %
-
Net Profit Growth Qtr YoY %249.15 %
-
Net Profit Growth Qtr QoQ %-72.01 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
384,666.1
|
217.7
|
L
 -0.4%
H
214.9
219.6
|
L
 0.9%
H
211.4
219.6
|
L
 6.8%
H
200.0
220.0
|
L
 -6.2%
H
190.8
237.1
|
L
 17.0%
H
181.7
244.8
|
L
 59.6%
H
131.0
244.8
|
L
 92.3%
H
105.6
244.8
|
L
 247.2%
H
55.1
244.8
|
| Adc Therapeutics SA |
|
432.4
|
3.4
|
L
 -1.5%
H
3.4
3.5
|
L
 0.3%
H
3.4
3.7
|
L
 -10.1%
H
3.1
4.1
|
L
 -17.1%
H
3.1
5.0
|
L
 10.0%
H
2.6
5.0
|
L
 49.1%
H
0.4
6.0
|
L
 -84.3%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
4,201.5
|
13.2
|
L
 1.7%
H
12.8
13.2
|
L
 6.0%
H
12.5
13.2
|
L
 2.9%
H
11.8
13.8
|
L
 -4.6%
H
11.7
14.0
|
L
 79.9%
H
7.1
15.4
|
L
 451.0%
H
2.3
15.4
|
L
 132.7%
H
1.2
15.4
|
L
 -60.7%
H
1.2
35.2
|
| Annovis Bio Inc |
|
81.7
|
1.9
|
L
 1.1%
H
1.9
2.0
|
L
 -13.9%
H
1.9
2.3
|
L
 4.4%
H
1.8
2.5
|
L
 -28.4%
H
1.5
3.0
|
L
 -18.3%
H
1.5
5.5
|
L
 -84.9%
H
1.1
22.5
|
L
 -95.7%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,001.8
|
5.4
|
L
 -0.9%
H
5.3
5.4
|
L
 -2.0%
H
5.3
5.6
|
L
 -4.1%
H
5.2
6.3
|
L
 -9.6%
H
4.9
6.3
|
L
 18.3%
H
4.4
8.7
|
L
 -34.6%
H
4.0
11.5
|
L
 -83.3%
H
4.0
32.5
|
L
 -81.1%
H
4.0
34.8
|
| Bristol-Myers Squibb |
|
116,765.6
|
57.2
|
L
 0.5%
H
56.5
57.3
|
L
 -3.8%
H
56.3
59.8
|
L
 -0.7%
H
55.4
60.8
|
L
 -8.3%
H
55.4
62.9
|
L
 18.4%
H
42.5
62.9
|
L
 -10.2%
H
39.4
66.5
|
L
 -13.0%
H
39.4
81.4
|
L
 -19.8%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
470.6
|
9.1
|
L
 -0.7%
H
9.1
9.4
|
L
 7.9%
H
8.5
9.4
|
L
 14.1%
H
7.5
9.7
|
L
 11.9%
H
7.5
9.7
|
L
 44.3%
H
5.6
14.1
|
L
 10.9%
H
1.4
15.1
|
L
 -85.0%
H
1.4
68.0
|
L
 -77.9%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
11,911.9
|
23.9
|
L
 -0.5%
H
23.6
24.4
|
L
 9.8%
H
21.6
24.4
|
L
 9.4%
H
19.4
26.3
|
L
 -9.7%
H
19.4
26.4
|
L
 77.5%
H
13.1
27.7
|
L
 195.2%
H
7.9
27.7
|
L
 -33.7%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
101,375.7
|
50.5
|
L
 -1.4%
H
50.5
51.3
|
L
 -1.6%
H
50.5
52.1
|
L
 -1.7%
H
49.4
52.6
|
L
 -14.5%
H
49.4
59.6
|
L
 23.2%
H
35.5
61.7
|
L
 49.3%
H
31.7
61.7
|
L
 28.0%
H
28.5
61.7
|
L
 16.1%
H
28.5
61.7
|
| Johnson & Johnson |
|
542,418.2
|
225.3
|
L
 -2.4%
H
224.6
231.5
|
L
 -3.3%
H
224.6
233.2
|
L
 -0.9%
H
220.4
235.5
|
L
 -9.3%
H
220.4
251.7
|
L
 45.2%
H
149.0
251.7
|
L
 46.0%
H
140.7
251.7
|
L
 33.1%
H
140.7
251.7
|
L
 99.3%
H
109.2
251.7
|
| Eli Lilly |
|
985,374.3
|
1,105
|
L
 -1.9%
H
1089
1132.7
|
L
 3.8%
H
1060.4
1149.1
|
L
 29.8%
H
896.8
1149.1
|
L
 5.0%
H
850.5
1149.1
|
L
 49.8%
H
623.8
1149.1
|
L
 158.6%
H
424.0
1149.1
|
L
 453.2%
H
196.7
1149.1
|
L
 1373.5%
H
64.2
1149.1
|
| Merck & Company |
|
293,217.6
|
118.7
|
L
 -1.0%
H
118.2
120.7
|
L
 -3.0%
H
118.2
123.1
|
L
 7%
H
108.6
123.1
|
L
 -4.1%
H
107.9
124
|
L
 54.5%
H
75.4
125.1
|
L
 8.7%
H
73.3
134.6
|
L
 64.0%
H
70.9
134.6
|
L
 120.3%
H
50.4
134.6
|
| Nuvation Bio Inc (Class A) |
|
1,664.4
|
4.8
|
L
 0.6%
H
4.6
4.8
|
L
 1.3%
H
4.6
5.0
|
L
 10.1%
H
4.1
5.2
|
L
 -19.1%
H
4.0
5.9
|
L
 125.5%
H
1.6
9.8
|
L
 204.5%
H
1.0
9.8
|
L
 -66.4%
H
1.0
14.5
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
201,954.3
|
45.6
|
L
 0.2%
H
45.2
45.9
|
L
 1.4%
H
44.0
46.1
|
L
 13.1%
H
41.7
47.8
|
L
 21.7%
H
35.1
47.8
|
L
 -36.3%
H
35.1
81.4
|
L
 -43.0%
H
35.1
148.2
|
L
 15.5%
H
35.1
148.2
|
L
 64.4%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
286,538.2
|
150.2
|
L
 -0.8%
H
150.1
152.0
|
L
 -1.2%
H
150.0
152.5
|
L
 5.1%
H
144.5
152.5
|
L
 -10.9%
H
142.3
167.6
|
L
 29.7%
H
112.3
170.5
|
L
 55.5%
H
92.2
170.5
|
L
 69.9%
H
74.1
170.5
|
L
 112.0%
H
59.2
170.5
|
| Organon & Co. |
|
3,503.1
|
13.3
|
L
 -0.1%
H
13.3
13.4
|
L
 -0.7%
H
13.3
13.4
|
L
H
13.3
13.5
|
L
 83.0%
H
5.7
13.5
|
L
 44.7%
H
5.7
13.5
|
L
 -30.8%
H
5.7
24.1
|
L
 -62.7%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,251.6
|
47.5
|
L
 -1.9%
H
47.2
48.8
|
L
 -1.0%
H
47.2
49.2
|
L
 -15.2%
H
42.6
56.8
|
L
 -31.4%
H
42.6
69.5
|
L
 -44.5%
H
42.6
87.1
|
L
 -18.1%
H
42.6
90.0
|
L
 -4.7%
H
42.6
90.0
|
L
 -13.0%
H
26.3
90.0
|
| Pfizer |
|
149,211.4
|
26.2
|
L
 0.2%
H
25.9
26.2
|
L
 1.1%
H
25.7
26.5
|
L
 -0.3%
H
25.2
26.9
|
L
 -5.3%
H
25.2
28.7
|
L
 11.5%
H
23.1
28.7
|
L
 -29.3%
H
20.9
40.4
|
L
 -32.4%
H
20.9
61.7
|
L
 -20.2%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,529.0
|
11.1
|
L
 -0.9%
H
11.0
11.4
|
L
 -1.5%
H
10.7
11.5
|
L
 -2.1%
H
10.5
12.6
|
L
 -14.5%
H
9.2
12.9
|
L
 -58.7%
H
9.2
28.4
|
L
 -65.0%
H
9.2
40.3
|
L
 -76.1%
H
9.2
50.9
|
L
 -88.6%
H
9.2
111
|
| Arcus Biosciences Inc |
|
3,187.1
|
25.3
|
L
 3.5%
H
24.1
25.5
|
L
 8.2%
H
23.1
25.5
|
L
 5.0%
H
22.6
26.7
|
L
 24.4%
H
20
28.7
|
L
 183.8%
H
7.9
28.7
|
L
 25.1%
H
6.5
28.7
|
L
 2.1%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,348.3
|
13.6
|
L
 0.8%
H
13.5
13.7
|
L
 0.2%
H
13.5
13.9
|
L
 -0.7%
H
12.2
13.9
|
L
 -5.2%
H
12.2
14.6
|
L
 -7.4%
H
12.2
16.2
|
L
 25.0%
H
10.9
74.9
|
L
 -4.5%
H
9.6
74.9
|
L
 47.2%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
50,411.5
|
16.0
|
L
 -1.2%
H
15.9
16.1
|
L
 -1.8%
H
15.8
16.3
|
L
 -2.1%
H
15.8
16.9
|
L
 -14.9%
H
15.8
18.9
|
L
 6.2%
H
13.0
18.9
|
L
 -0.7%
H
12.6
18.9
|
L
 -6.6%
H
12.3
18.9
|
L
 -26.9%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
41,127.6
|
35.3
|
L
 2.3%
H
34.5
35.5
|
L
 3.7%
H
33.7
35.5
|
L
 -0.2%
H
33.6
37.0
|
L
 4.3%
H
27.9
37.0
|
L
 110.5%
H
15.0
37.3
|
L
 389.9%
H
7.1
37.3
|
L
 239.6%
H
6.8
37.3
|
L
 -31.6%
H
6.1
56.4
|
| Usana Health Sciences Inc |
|
337.9
|
18.3
|
L
 -2.9%
H
18.2
18.9
|
L
 -2.4%
H
18.0
19.5
|
L
 -2.2%
H
16.9
21
|
L
 -15.0%
H
16.6
21.1
|
L
 -38.7%
H
16.6
38.3
|
L
 -70.7%
H
16.6
69.6
|
L
 -82.7%
H
16.6
107.9
|
L
 -69.8%
H
16.6
138.0
|
| Zoetis (Class A) |
|
32,569.8
|
77.7
|
L
 -0.7%
H
77.4
78.9
|
L
 -4.5%
H
77.4
81.3
|
L
 -31.8%
H
72.4
116.3
|
L
 -40.7%
H
72.4
130.1
|
L
 -53.9%
H
72.4
172.2
|
L
 -51.7%
H
72.4
201.9
|
L
 -56.0%
H
72.4
249.3
|
L
 64.7%
H
45.3
249.3
|
| Biohaven Ltd |
|
1,657.7
|
11.0
|
L
 7.5%
H
10.6
12
|
L
 16.5%
H
9.5
12
|
L
 19.7%
H
8.2
12
|
L
 -4.4%
H
8.0
12.1
|
L
 -25.7%
H
7.5
18.6
|
L
 -32.4%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
233.4
|
4.7
|
L
 -1.3%
H
4.6
4.9
|
L
 5.1%
H
4.5
5.2
|
L
 16.8%
H
3.7
5.5
|
L
 34.5%
H
3.0
5.5
|
L
 179.3%
H
1.6
5.5
|
L
 -38.9%
H
1.2
8.5
|
L
 -81.5%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,884.2
|
6.2
|
L
 7.7%
H
5.5
6.2
|
L
 18.7%
H
5.1
6.2
|
L
 61.5%
H
3.8
6.2
|
L
 70.9%
H
3.2
6.2
|
L
 205.5%
H
2.0
6.5
|
L
 -11.2%
H
1.9
8.1
|
L
 -77.0%
H
1.9
27.6
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
329.4
|
5.8
|
L
H
5.8
5.9
|
L
 6.3%
H
5.4
5.9
|
L
 8.2%
H
5.1
6.1
|
L
 12.9%
H
4.2
6.1
|
L
 -7.4%
H
4
7.5
|
L
 87.7%
H
2.9
9.0
|
L
 -86.0%
H
2.2
48
|
L
 -92.9%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
3,530.1
|
58.5
|
L
 1.0%
H
56.9
59
|
L
 -3.4%
H
56.6
61.8
|
L
 -14.1%
H
55.0
71.0
|
L
 70.1%
H
31.3
91
|
L
 434.0%
H
10.8
91
|
L
 134.5%
H
2.2
91
|
L
 39.8%
H
2.2
91
|
L
 -91.9%
H
2.2
848.9
|
| Acumen Pharma Inc |
|
187.8
|
2.6
|
L
 2.4%
H
2.5
2.6
|
L
 3.6%
H
2.4
2.6
|
L
 11.1%
H
2.1
2.7
|
L
 -17.2%
H
2.1
3.6
|
L
 154.9%
H
1
3.6
|
L
 -47.4%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
900.8
|
4.6
|
L
 -0.9%
H
4.5
4.7
|
L
 4.8%
H
4.3
4.8
|
L
 10.4%
H
4.1
4.8
|
L
 -2.2%
H
4.0
4.9
|
L
 35.7%
H
3.0
5.1
|
L
 84.6%
H
1.7
5.1
|
L
 61.1%
H
1.7
6.5
|
L
 11.2%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
36.7
|
1.4
|
L
H
1.4
1.5
|
L
 23.7%
H
1.1
1.5
|
L
 36.9%
H
1
1.5
|
L
 7.6%
H
0.9
1.8
|
L
 2.9%
H
0.9
5.5
|
L
 -79.3%
H
0.4
7
|
L
 -97.4%
H
0.4
116.9
|
L
 -99.6%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,709.0
|
21.7
|
L
 0.1%
H
21.6
22.0
|
L
 2.7%
H
20.9
22.0
|
L
 -2.4%
H
20.3
23.1
|
L
 -11.8%
H
19.9
24.3
|
L
 0.4%
H
19.7
28.4
|
L
 -9.0%
H
13.4
33.9
|
L
 -3.0%
H
12.2
33.9
|
L
 -39.2%
H
12.2
58.7
|
| Adicet Bio Inc |
|
87.0
|
9.3
|
L
 7.8%
H
8.5
9.5
|
L
 12.2%
H
8.0
9.5
|
L
 22.0%
H
7.1
9.5
|
L
 28.4%
H
6.0
9.5
|
L
 -19.0%
H
6.0
17.4
|
L
 -89.6%
H
6.0
93.0
|
L
 -95.7%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
537.9
|
5.2
|
L
 -1.1%
H
5.2
5.5
|
L
 11.7%
H
4.5
5.5
|
L
 26.3%
H
4.2
6.2
|
L
 14.9%
H
2.6
6.2
|
L
 46.4%
H
2
6.2
|
L
 -16.0%
H
1.8
6.9
|
L
 -34.6%
H
1.8
10.3
|
L
 -99.8%
H
1.8
2904
|
| AC Immune SA |
|
270.7
|
2.7
|
L
 -3.3%
H
2.7
2.8
|
L
 -6.0%
H
2.7
3.0
|
L
 -9.2%
H
2.7
3.2
|
L
 -9.2%
H
2.6
3.5
|
L
 55.6%
H
1.6
4
|
L
 25.5%
H
1.4
5.1
|
L
 -56.3%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
635.5
|
4.6
|
L
 -0.4%
H
4.5
4.7
|
L
 0.7%
H
4.5
4.7
|
L
 1.8%
H
4.2
5.2
|
L
 58.5%
H
2.8
5.2
|
L
 211.6%
H
1.3
5.2
|
L
 -44.4%
H
0.6
11.1
|
L
 -79.5%
H
0.6
24
|
L
 -77.3%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
68.5
|
1.6
|
L
 -1.8%
H
1.6
1.7
|
L
 -8.6%
H
1.6
1.8
|
L
 -11.6%
H
1.6
2.2
|
L
 6.0%
H
1.3
2.2
|
L
 52.4%
H
1.1
3.6
|
L
 -87.2%
H
1.1
14.0
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
13.9
|
0.8
|
L
H
0.8
0.8
|
L
H
0.8
0.9
|
L
 1.2%
H
0.8
1.0
|
L
 -9.9%
H
0.7
1.0
|
L
 67.4%
H
0.4
1.6
|
L
 -16.3%
H
0.4
1.6
|
L
 -97.1%
H
0.4
33.4
|
L
 -98.8%
H
0.4
115
|
| Grace Therapeutics Inc |
|
39.8
|
2.6
|
L
 5.8%
H
2.4
2.6
|
L
 16.8%
H
2.2
2.6
|
L
 22.4%
H
2.1
2.6
|
L
 -40.1%
H
1.8
5.2
|
L
 -7.2%
H
1.8
5.2
|
L
 -23.5%
H
1.7
5.2
|
L
 -89.3%
H
1.7
32.6
|
L
 -96.4%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
8.5
|
2.0
|
L
 -0.5%
H
1.9
2.0
|
L
 0.5%
H
1.9
2.1
|
L
 0.5%
H
1.8
2.3
|
L
 32%
H
1.3
7.5
|
L
 -74.6%
H
1.3
21
|
L
 -96.6%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
5.1
|
2.4
|
L
 -5.1%
H
2.3
2.5
|
L
 15.4%
H
2.0
2.6
|
L
 54.8%
H
1.3
2.6
|
L
 -5.1%
H
1.3
2.6
|
L
 -86.0%
H
1.3
18.9
|
L
 -98.6%
H
1.3
350
|
L
 -99.8%
H
1.3
3175
|
L
H
1.3
5900
|
| Adma Biologics Inc |
|
1,849.5
|
8.0
|
L
 0.6%
H
8.0
8.2
|
L
 -3.2%
H
7.9
8.3
|
L
 -24.7%
H
7.5
10.9
|
L
 -48.8%
H
7.2
17.2
|
L
 -59.8%
H
7.2
22.4
|
L
 97.5%
H
3.1
25.7
|
L
 356%
H
1.0
25.7
|
L
 8.1%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,424.7
|
15.2
|
L
 -0.3%
H
15.1
15.6
|
L
 9.2%
H
13.7
15.6
|
L
 12.0%
H
12.5
15.6
|
L
 -5.4%
H
12
17.0
|
L
 59.1%
H
9.3
20.8
|
L
 116.7%
H
2.3
20.8
|
L
 -59.9%
H
2.3
43.4
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.1
|
0.1
|
L
 -25%
H
0.1
0.2
|
L
 -76.9%
H
0.1
0.4
|
L
 -98.0%
H
0.1
5.9
|
L
 -99.9%
H
0.1
117.9
|
L
 -100%
H
0.1
53453.5
|
L
 -100.0%
H
0.1
10000000000
|
L
 -100.0%
H
0.1
10000000000
|
L
H
0.1
10000000000
|
| Agenus Inc |
|
145.7
|
3.5
|
L
 2.9%
H
3.3
3.5
|
L
 12.5%
H
3.1
3.5
|
L
 -8.9%
H
3.0
4.3
|
L
 5.1%
H
2.9
5.1
|
L
 2.0%
H
2.7
7.3
|
L
 -88.0%
H
1.4
196
|
L
 -95.8%
H
1.4
196
|
L
 -95.6%
H
1.4
196
|
| Agios Pharma Inc |
|
1,748.5
|
29.4
|
L
 -3.4%
H
28.5
30.3
|
L
 4.5%
H
27.5
30.5
|
L
 4.8%
H
26.5
30.5
|
L
 -2.8%
H
24.3
36.4
|
L
 -8.4%
H
22.2
46
|
L
 16.1%
H
19.8
62.6
|
L
 -47.3%
H
16.8
62.6
|
L
 -44.9%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
297.6
|
73.5
|
L
 1.9%
H
71.5
74.4
|
L
 -0.7%
H
71.1
76.1
|
L
 2.2%
H
64.7
78.8
|
L
 70.9%
H
38.4
78.8
|
L
 381.0%
H
13.9
78.8
|
L
 2175.5%
H
2.7
78.8
|
L
 -55.5%
H
2.7
212.5
|
L
 -59.4%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
273.6
|
1.0
|
L
 -2.9%
H
1.0
1.1
|
L
H
1.0
1.1
|
L
 -25%
H
0.9
1.5
|
L
 -22.1%
H
0.9
1.6
|
L
 -66.3%
H
0.9
4.1
|
L
 6.3%
H
0.8
4.1
|
L
 -70.9%
H
0.2
4.3
|
L
 -88.4%
H
0.2
20.3
|
| Avalon GloboCare Corp |
|
4.3
|
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 -5.3%
H
0.3
0.4
|
L
 -10%
H
0.2
0.4
|
L
 -75.8%
H
0.2
1.3
|
L
 -90.2%
H
0.2
4.7
|
L
 -80%
H
0.2
11.7
|
L
 -96.8%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
105.6
|
1.8
|
L
H
1.7
1.8
|
L
 12.9%
H
1.5
1.8
|
L
 16.7%
H
1.5
1.9
|
L
 -68.0%
H
1.1
5.7
|
L
 -18.6%
H
1.1
6.2
|
L
 -81.3%
H
1.1
12.0
|
L
 -86.0%
H
1.1
13.2
|
L
 -71.0%
H
1.1
16.7
|
| Alector Inc |
|
239.8
|
2.2
|
L
 0.5%
H
2.1
2.3
|
L
 -2.3%
H
2.1
2.3
|
L
 -6.1%
H
2
2.7
|
L
 -11.1%
H
1.9
2.7
|
L
 62.4%
H
1.1
3.4
|
L
 -70.6%
H
0.9
9.1
|
L
 -87.9%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
35.3
|
5.7
|
L
 -1.6%
H
5.5
5.9
|
L
 -1.0%
H
5.5
6.0
|
L
 -4.5%
H
5.2
6.9
|
L
 -18.9%
H
5.2
9.0
|
L
 7.8%
H
5.1
13.7
|
L
 -80%
H
3.8
46.3
|
L
 -99.2%
H
3.8
857.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
7,032.1
|
42.2
|
L
 5.6%
H
39.6
42.8
|
L
 14.7%
H
36.5
42.8
|
L
 25.2%
H
33.1
42.8
|
L
 40.2%
H
27
42.8
|
L
 37.8%
H
25.2
42.8
|
L
 44.6%
H
22.0
42.8
|
L
 86.1%
H
21.2
42.8
|
L
 -8.5%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
749.0
|
2.2
|
L
 -3.6%
H
2.0
2.2
|
L
 8.5%
H
2.0
2.3
|
L
 2.8%
H
1.8
2.4
|
L
 -21.9%
H
1.8
4.5
|
L
 85.5%
H
1.0
4.5
|
L
 -58.2%
H
0.9
6.1
|
L
 -91.6%
H
0.9
27.9
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
26.1
|
1.6
|
L
 -1.8%
H
1.6
1.7
|
L
 -7.3%
H
1.6
1.8
|
L
 18.8%
H
1.2
1.8
|
L
 69.1%
H
1.0
1.8
|
L
 88.5%
H
0.8
2.1
|
L
 -99.2%
H
0.1
269.8
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
40,318.1
|
302.0
|
L
 -1.0%
H
297.6
305.7
|
L
 1.5%
H
291.8
306.0
|
L
 0.3%
H
284.3
317.6
|
L
 -9.3%
H
284.3
343.4
|
L
 -0.9%
H
284.3
495.6
|
L
 62.0%
H
142.0
495.6
|
L
 112.7%
H
117.6
495.6
|
L
 346.9%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
94.9
|
1.1
|
L
H
1.1
1.2
|
L
 7.8%
H
1.0
1.2
|
L
 -13.3%
H
1.0
1.4
|
L
 -2.6%
H
1.0
2.1
|
L
 -43.1%
H
1.0
2.2
|
L
 -26%
H
1.0
7.4
|
L
 -95.5%
H
1.0
28
|
L
H
1.0
309.6
|
| Altimmune Inc |
|
593.1
|
3.1
|
L
 -0.7%
H
3.0
3.1
|
L
 5.2%
H
2.9
3.1
|
L
 16.0%
H
2.6
3.3
|
L
 -29.2%
H
2.6
4.4
|
L
 -43.8%
H
2.6
7.7
|
L
 -23.8%
H
2.1
14.8
|
L
 -75.9%
H
2.1
23.5
|
L
 -99.5%
H
1.5
1050
|
| Alvotech |
|
1,048.5
|
3.4
|
L
 -2.0%
H
3.4
3.5
|
L
 0.6%
H
3.4
3.5
|
L
 1.8%
H
3.2
3.7
|
L
 -15.8%
H
3.0
4.2
|
L
 -70.6%
H
3.0
11.9
|
L
 -58.9%
H
3.0
18
|
L
H
3.0
18
|
L
H
3.0
18
|
| Kalaris Therapeutics Inc |
|
125.4
|
5.3
|
L
 1.7%
H
5.1
5.4
|
L
 7.1%
H
5.1
5.6
|
L
 -4.4%
H
4.5
5.7
|
L
 -49.6%
H
4.5
10.7
|
L
 81.7%
H
2.1
11.9
|
L
 41.7%
H
0.4
12.9
|
L
 -77.5%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
4.5
|
1.2
|
L
 3.5%
H
1.1
1.2
|
L
 5.3%
H
1.1
1.2
|
L
 12.3%
H
1
1.3
|
L
 -40.8%
H
0.8
2.4
|
L
 -68.9%
H
0.8
4.3
|
L
 -99.9%
H
0.8
1071.9
|
L
H
0.8
45292.5
|
L
H
0.8
45292.5
|
| Amgen |
|
181,768.3
|
336.8
|
L
 0.1%
H
333.1
337.5
|
L
 -0.7%
H
333.1
342.5
|
L
 -0.4%
H
320.5
349.5
|
L
 -13.2%
H
320.5
391.3
|
L
 16.9%
H
267.8
391.3
|
L
 54.1%
H
211.7
391.3
|
L
 41.5%
H
198.6
391.3
|
L
 114.9%
H
133.6
391.3
|
| Amylyx Pharma Inc |
|
1,595.5
|
14.4
|
L
 0.9%
H
14.0
14.4
|
L
 5.7%
H
13.4
14.4
|
L
 -8.0%
H
12.4
16.9
|
L
 -5.4%
H
12.4
18.6
|
L
 178.6%
H
4.8
18.6
|
L
 -40.3%
H
1.6
26.4
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
831.2
|
18.9
|
L
 -2.3%
H
18.6
19.5
|
L
 2.4%
H
18.5
19.6
|
L
 -12.9%
H
16.6
24.3
|
L
 -6.8%
H
16.6
24.3
|
L
 -26.7%
H
16.6
31.3
|
L
 -57.5%
H
16.6
67.7
|
L
 -0.4%
H
16.6
67.7
|
L
 19.7%
H
12.1
67.7
|
| AnaptysBio Inc |
|
1,620.0
|
55.7
|
L
 -2.4%
H
54.9
57.4
|
L
 -6.8%
H
54.9
60.0
|
L
 -10.7%
H
54.9
72.4
|
L
 1.1%
H
44
73.3
|
L
 150.4%
H
17.1
73.3
|
L
 200.1%
H
12.2
73.3
|
L
 133.2%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,784.9
|
78.5
|
L
 -3.2%
H
78.1
81.3
|
L
 -5.1%
H
78.1
83.8
|
L
 0.7%
H
76.1
87.8
|
L
 6.2%
H
70.2
87.8
|
L
 33.7%
H
58.7
99.5
|
L
 74.7%
H
44.3
99.5
|
L
 128.6%
H
22.3
99.5
|
L
 50.2%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
90.5
|
2.7
|
L
H
2.7
2.8
|
L
 -3.2%
H
2.6
2.8
|
L
 -6.3%
H
2.6
3.2
|
L
 -9.4%
H
2.4
3.2
|
L
 5.1%
H
2.4
5.5
|
L
 -14.6%
H
2.1
5.5
|
L
 -32.0%
H
2.1
6.5
|
L
 -14.8%
H
0.6
8.1
|
| Annexon Inc |
|
888.0
|
5.4
|
L
 0.9%
H
5.2
5.5
|
L
 2.1%
H
5.2
5.6
|
L
 -8.0%
H
4.8
6.0
|
L
 -3.2%
H
4.8
6.6
|
L
 165.7%
H
1.9
7.2
|
L
 98.5%
H
1.3
8.4
|
L
 -74.3%
H
1.3
24.9
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
155.9
|
4.3
|
L
 -2.9%
H
4.3
4.7
|
L
 -10.7%
H
4.3
5.1
|
L
 -7.5%
H
3.9
5.2
|
L
 293.6%
H
1.1
6.9
|
L
 308.5%
H
1
6.9
|
L
 -14.9%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
3.1
|
0.4
|
L
 10.3%
H
0.4
0.5
|
L
 13.2%
H
0.4
0.5
|
L
 -15.7%
H
0.4
0.5
|
L
 -38.6%
H
0.4
0.9
|
L
 -91.5%
H
0.4
7.2
|
L
 -100.0%
H
0.4
27900
|
L
 -100.0%
H
0.4
121500
|
L
 -100.0%
H
0.4
2167200
|
| Apollomics Inc (Class A) |
|
31.1
|
14.2
|
L
 0.6%
H
13.8
15.7
|
L
 0.5%
H
13.3
16
|
L
 8.2%
H
13
17
|
L
 -30.0%
H
12.6
20.8
|
L
 132.0%
H
3.7
42.1
|
L
 -96.6%
H
0.1
645
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Aptorum Grp Ltd (Class A) |
|
8.4
|
1.0
|
L
 22.6%
H
0.8
1.0
|
L
 21.2%
H
0.8
1.0
|
L
 15.7%
H
0.8
1.0
|
L
 32.1%
H
0.8
1.3
|
L
 12.0%
H
0.7
4.5
|
L
 -66.8%
H
0.5
17.5
|
L
 -96.3%
H
0.5
35
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
11.0
|
0.9
|
L
 -4.3%
H
0.9
1.0
|
L
 -6.3%
H
0.9
1.0
|
L
 8.5%
H
0.8
1.1
|
L
 -3.3%
H
0.6
1.1
|
L
 -48.9%
H
0.6
2.2
|
L
 -76.6%
H
0.6
8.9
|
L
 -98.9%
H
0.6
156
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
6.1
|
4.9
|
L
 -1.8%
H
4.8
5.1
|
L
 -0.8%
H
4.4
5.1
|
L
 2.1%
H
4.3
5.6
|
L
 -32.9%
H
3.8
7.3
|
L
 -94.2%
H
3.8
236.0
|
L
 -100.0%
H
3.8
1078387.2
|
L
 -100.0%
H
3.8
18613900.8
|
L
H
3.8
68020444.8
|
| AquaBounty Tech Inc |
|
5.4
|
1.0
|
L
H
0.9
1.1
|
L
 6.1%
H
0.9
1.1
|
L
 11.8%
H
0.9
1.1
|
L
 7.2%
H
0.9
1.2
|
L
 26.8%
H
0.7
3.0
|
L
 -89.6%
H
0.5
10.1
|
L
 -99.0%
H
0.5
130.6
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
504.3
|
4.0
|
L
H
4.0
4.1
|
L
 -2.4%
H
4.0
4.2
|
L
 -0.7%
H
4.0
5.0
|
L
 0.5%
H
3.8
5.0
|
L
 48.3%
H
2.7
7.6
|
L
 95.1%
H
1.3
7.6
|
L
 8.4%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
225.1
|
7.9
|
L
H
7.8
8.1
|
L
 12.7%
H
7.1
8.1
|
L
 -5.7%
H
6.7
9.6
|
L
 -3.8%
H
6.4
9.6
|
L
 -36.8%
H
5.9
24.2
|
L
 -70.2%
H
5.9
45
|
L
 -72.9%
H
5.9
65
|
L
 -77.9%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,492.1
|
6.0
|
L
 -3.4%
H
6.0
6.3
|
L
 -1.2%
H
6.0
6.4
|
L
 0.5%
H
6
7.4
|
L
 -7.8%
H
5.1
7.4
|
L
 64.6%
H
3.5
8.4
|
L
 87.0%
H
3.2
10.1
|
L
 -15.5%
H
0.5
10.1
|
L
 -31.8%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
2,684.3
|
21.5
|
L
 0.1%
H
21.1
21.6
|
L
 2.9%
H
20.7
22.1
|
L
 -4.1%
H
19.3
24.3
|
L
 -20.4%
H
19.3
26.1
|
L
 64.6%
H
12.7
31.8
|
L
 174.8%
H
1.8
31.8
|
L
 -18.6%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
4.9
|
1.4
|
L
 -4.1%
H
1.4
1.5
|
L
 17.7%
H
1.2
1.9
|
L
 -58.9%
H
1.2
3.6
|
L
 -60.8%
H
1.2
19.9
|
L
 -92.6%
H
1.2
85.8
|
L
 -95.5%
H
1.2
85.8
|
L
 -99.6%
H
1.2
359.1
|
L
H
1.2
46656
|
| Arvinas Inc |
|
579.4
|
9.0
|
L
 1.6%
H
8.6
9.0
|
L
 -1.2%
H
8.6
9.2
|
L
 -8.6%
H
8.4
11.4
|
L
 -32.3%
H
8.4
14.5
|
L
 24.7%
H
6.1
14.5
|
L
 -59.0%
H
5.9
53.1
|
L
 -87.7%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
10,974.2
|
77.9
|
L
 -1.4%
H
76.5
78.8
|
L
 4.0%
H
74.1
80.2
|
L
 10.5%
H
69.2
82.3
|
L
 23.1%
H
54.0
82.3
|
L
 384.8%
H
14.3
82.3
|
L
 137.7%
H
9.6
82.3
|
L
 7.3%
H
9.6
93.7
|
L
 1222.8%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
548.1
|
27.7
|
L
 -0.3%
H
27.3
28.5
|
L
 -2.4%
H
27
29.1
|
L
 5.1%
H
25.8
32.5
|
L
 -7.3%
H
25.8
32.5
|
L
 95.5%
H
14.2
39.7
|
L
 142.6%
H
7.7
39.7
|
L
 -41.9%
H
7.7
56.3
|
L
 -57.2%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
979.5
|
7.8
|
L
 0.1%
H
7.4
8.1
|
L
 40.2%
H
6.4
8.1
|
L
 57.5%
H
4.8
8.1
|
L
 45.7%
H
3.9
8.1
|
L
 2.9%
H
3.9
14.5
|
L
 2122.9%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
151.5
|
23.4
|
L
H
23.4
23.4
|
L
H
23.4
23.5
|
L
 29.9%
H
18.1
23.5
|
L
 101.0%
H
11.1
23.5
|
L
 135.3%
H
8.6
23.5
|
L
 -75.8%
H
7.7
98.6
|
L
 -13.7%
H
7.7
120.2
|
L
 -98.1%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,667.8
|
4.5
|
L
 2.7%
H
4.4
4.6
|
L
 4.9%
H
4.2
4.6
|
L
 10.0%
H
3.9
4.6
|
L
 24.8%
H
3.3
5.5
|
L
 96.1%
H
2
6.8
|
L
 153.1%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| LeonaBio Inc |
|
89.6
|
9.5
|
L
 -1.0%
H
9.5
9.8
|
L
 -7.7%
H
9.5
11.1
|
L
 8.8%
H
8.2
11.4
|
L
 69.5%
H
5.1
14.2
|
L
 204.8%
H
2.7
14.2
|
L
 -64.7%
H
2.2
43.0
|
L
 -95.2%
H
2.2
236.4
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
64.4
|
4.4
|
L
 3.8%
H
4.2
4.5
|
L
 -2.4%
H
4.0
4.7
|
L
 -14.5%
H
3.6
5.9
|
L
 25.5%
H
1.8
5.9
|
L
 -56.8%
H
1.8
174.6
|
L
 -98.0%
H
1.8
260.3
|
L
 -100.0%
H
1.8
44650
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
45.0
|
5.2
|
L
 0.8%
H
5
5.3
|
L
 5.4%
H
4.9
5.3
|
L
 -1.0%
H
4.7
6.2
|
L
 18.1%
H
4.2
6.3
|
L
 -55.2%
H
3.8
19.4
|
L
 -62.1%
H
3.8
34.7
|
L
 -89.2%
H
3.8
147
|
L
 -99.4%
H
3.8
1000.4
|
| Atara Biotherapeutics Inc |
|
94.7
|
10.5
|
L
 -6.7%
H
10.3
11.3
|
L
 7.2%
H
9.2
11.4
|
L
 128.5%
H
4.6
12.5
|
L
 93.9%
H
4.3
12.5
|
L
 34.7%
H
3.9
19.1
|
L
 -74.0%
H
0.4
63.4
|
L
 -96.9%
H
0.4
501
|
L
 -97.6%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
1,971.5
|
15.3
|
L
 -0.1%
H
15.0
15.4
|
L
 0.7%
H
15
16.1
|
L
 0.3%
H
14.4
16.3
|
L
 8.2%
H
13.8
16.9
|
L
 95.5%
H
7.3
16.9
|
L
 69.4%
H
4.7
16.9
|
L
 5.6%
H
4.1
34.0
|
L
 508.3%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
772.3
|
7.5
|
L
 -0.4%
H
7.4
7.6
|
L
 -1.7%
H
7.4
7.9
|
L
 11%
H
6.7
9.5
|
L
 26.8%
H
5.3
9.5
|
L
 27.5%
H
4.7
9.5
|
L
 -34.5%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
373.7
|
4.7
|
L
 -1.3%
H
4.5
4.7
|
L
 5.7%
H
4.4
4.8
|
L
 -14%
H
4.0
5.8
|
L
 -0.2%
H
4.0
6.5
|
L
 57.2%
H
2.8
6.5
|
L
 13.3%
H
2.5
6.5
|
L
 -77.1%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
588.0
|
31.2
|
L
 4.6%
H
29.5
31.9
|
L
 7.0%
H
28.6
32.3
|
L
 15.1%
H
26.3
32.3
|
L
 32.9%
H
21.7
36.0
|
L
 44.9%
H
14.4
36.0
|
L
 133.9%
H
1.4
61.1
|
L
 -71.1%
H
1.4
132
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,038.5
|
21.0
|
L
 1.0%
H
20.4
21.7
|
L
 -5.3%
H
20.3
22.8
|
L
 -5.7%
H
20.3
26.8
|
L
 41.9%
H
12.9
28
|
L
 190.2%
H
6.6
28
|
L
 -96.2%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
838.4
|
16.0
|
L
 -1.1%
H
15.7
16.4
|
L
 -2.5%
H
15.3
16.6
|
L
 20.8%
H
12.6
24.3
|
L
 -8.9%
H
12.5
24.3
|
L
 298.8%
H
3.9
24.3
|
L
 455.7%
H
0.0
34.5
|
L
 -49.7%
H
0.0
44.4
|
L
 -46.6%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
280.8
|
3.0
|
L
 3.1%
H
2.8
3.0
|
L
 12.2%
H
2.7
3.0
|
L
 -7.1%
H
2.6
3.5
|
L
 -31.6%
H
2.6
5.2
|
L
 -59.8%
H
2.6
14.0
|
L
 -67.0%
H
2.6
14.4
|
L
 -75.7%
H
2.6
31.5
|
L
 -32.1%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
12,066.3
|
234.5
|
L
 0.7%
H
230.0
236.5
|
L
 -0.6%
H
230.0
238.6
|
L
 27.5%
H
183.9
238.6
|
L
 43.1%
H
152.3
238.6
|
L
 123.0%
H
96.1
238.6
|
L
 237.6%
H
55.0
238.6
|
L
 286.2%
H
19.4
238.6
|
L
 2823.7%
H
1.9
238.6
|
| Aytu BioPharma Inc |
|
24.6
|
2.3
|
L
 2.2%
H
2.2
2.3
|
L
 4.6%
H
2.1
2.3
|
L
 -9.1%
H
2.0
2.6
|
L
 -10.9%
H
2.0
2.8
|
L
 28.7%
H
1.5
3.1
|
L
 35.5%
H
1.0
3.5
|
L
 -97.7%
H
1.0
123.6
|
L
 -100.0%
H
1.0
518400
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.2
|
L
 3.6%
H
1.1
1.2
|
L
H
1.1
1.3
|
L
 16%
H
1.0
1.3
|
L
 0.9%
H
1.0
1.4
|
L
 -35.6%
H
0.5
2.6
|
L
 -44.2%
H
0.5
2.8
|
L
 -90.8%
H
0.5
12.9
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
262.3
|
4.0
|
L
 0.8%
H
3.8
4.2
|
L
 5.9%
H
3.4
4.3
|
L
 11.8%
H
3.1
4.3
|
L
 34.1%
H
2.8
4.8
|
L
 104.6%
H
1.3
4.8
|
L
 200.8%
H
1.1
4.8
|
L
 -72.0%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
8.4
|
6.7
|
L
 -2.5%
H
6.7
6.7
|
L
 -2.6%
H
6.6
6.8
|
L
 -5%
H
6.0
7.4
|
L
 -8.7%
H
5.4
7.6
|
L
 -17.1%
H
5.4
12.1
|
L
 -48.3%
H
5
27.9
|
L
 -96.4%
H
5
229.6
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
18.8
|
16.4
|
L
 -25.5%
H
15.7
26.0
|
L
 -10.1%
H
13.7
29.3
|
L
 213.6%
H
3.0
29.3
|
L
 74.1%
H
3.0
29.3
|
L
 -69.6%
H
3.0
56.8
|
L
 -88.9%
H
3.0
219.8
|
L
 -98.9%
H
3.0
1512
|
L
 -99.9%
H
3.0
17759.8
|
| Amarin Corp (ADR) |
|
303.8
|
14.5
|
L
 0.6%
H
14.4
14.8
|
L
 0.4%
H
14.0
14.8
|
L
 1.4%
H
13.0
15.6
|
L
 5%
H
13.0
17
|
L
 25.0%
H
11.4
20.9
|
L
 1149.1%
H
0.4
20.9
|
L
 219.2%
H
0.4
20.9
|
L
 679.0%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
51,988.4
|
836.0
|
L
 -0.3%
H
829.6
841.9
|
L
 3.7%
H
799.4
843.9
|
L
 7.7%
H
775.0
843.9
|
L
 9.0%
H
661.9
852.3
|
L
 45.8%
H
510.1
934.6
|
L
 113.1%
H
327.7
934.6
|
L
 199.6%
H
249.5
934.6
|
L
H
17.3
934.6
|
| Ascendis Pharma A/S (ADR) |
|
13,758.8
|
224.1
|
L
 -5.6%
H
218.1
236
|
L
 -9.3%
H
218.1
245.2
|
L
 1.7%
H
218.1
250.3
|
L
 -4.0%
H
212.6
250.7
|
L
 37.6%
H
160.9
250.7
|
L
 161.3%
H
83.8
250.7
|
L
 66.8%
H
61.6
250.7
|
L
 1501.9%
H
11.9
250.7
|
| Alterity Therapeutics Ltd (ADR) |
|
74.7
|
4.1
|
L
 1.0%
H
4.0
4.1
|
L
 -0.5%
H
3.9
4.4
|
L
 -9.7%
H
3.8
5.0
|
L
 19.8%
H
3.1
5.3
|
L
 -8.4%
H
2.7
7
|
L
 48.2%
H
1
7
|
L
 -69.3%
H
1
27.5
|
L
 -89.1%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
497.7
|
1.9
|
L
 5.7%
H
1.7
1.9
|
L
 10%
H
1.7
1.9
|
L
 32.6%
H
1.4
2.0
|
L
 9.4%
H
1.2
2.0
|
L
 6.9%
H
1.2
2.7
|
L
 -41.7%
H
1.1
7.5
|
L
 -71.8%
H
1.1
8.2
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
575,682.3
|
185.7
|
L
 0.2%
H
184.7
187.1
|
L
 -0.7%
H
183.4
188.7
|
L
 0.3%
H
180
191.5
|
L
 -10.9%
H
180
207.3
|
L
 -1.5%
H
180
212.7
|
L
 -1.5%
H
180
212.7
|
L
 -1.5%
H
180
212.7
|
L
 -1.5%
H
180
212.7
|
| BridgeBio Pharma Inc |
|
12,977.8
|
66.3
|
L
 -3.2%
H
66.1
68.2
|
L
 -4.1%
H
65.4
68.8
|
L
 -6.6%
H
63.6
72.5
|
L
 -0.3%
H
62.8
84.8
|
L
 93.5%
H
34.1
84.9
|
L
 389.4%
H
13.3
84.9
|
L
 11.9%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
6.5
|
3.9
|
L
 -3.0%
H
3.8
4.0
|
L
 6.5%
H
3.4
4.2
|
L
 -2.7%
H
3.3
5.2
|
L
 -68.2%
H
3.3
10.6
|
L
 -80.8%
H
3.3
71.5
|
L
 -97.4%
H
3.3
201
|
L
 -99.8%
H
3.3
2591.5
|
L
H
3.3
3831.5
|
| BioCardia Inc |
|
10.6
|
0.9
|
L
 1.1%
H
0.9
1.0
|
L
 -3.1%
H
0.9
1.0
|
L
 -15.5%
H
0.8
1.2
|
L
 -27.9%
H
0.8
1.4
|
L
 -56.9%
H
0.8
2.5
|
L
 -96.5%
H
0.8
43.8
|
L
 -98.5%
H
0.8
76.5
|
L
 -99.6%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,264.6
|
8.9
|
L
 -2.1%
H
8.8
9.1
|
L
 7.5%
H
8.1
9.2
|
L
 -0.9%
H
7.8
9.8
|
L
 1.8%
H
7.8
10.3
|
L
 -17.1%
H
6
11.3
|
L
 11.9%
H
4.0
11.3
|
L
 -43.5%
H
4.0
20.0
|
L
 163.6%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
26.4
|
3.6
|
L
 1.7%
H
3.5
3.7
|
L
 4.3%
H
3.4
3.7
|
L
 -9.5%
H
3.0
4.3
|
L
 -4.7%
H
3.0
4.7
|
L
 -98.9%
H
3.0
369
|
L
 -100.0%
H
3.0
11275.5
|
L
 -99.9%
H
3.0
18526.5
|
L
 -100.0%
H
3.0
83250
|
| Black Diamond Therapeutics Inc |
|
127.2
|
2.2
|
L
 -1.3%
H
2.2
2.3
|
L
 -2.6%
H
2.2
2.5
|
L
 -13.6%
H
2.2
4.0
|
L
 -10.1%
H
1.9
4.0
|
L
 0.9%
H
1.9
4.9
|
L
 19.4%
H
1.2
7.7
|
L
 -83.1%
H
1.2
13.6
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,387.8
|
32.9
|
L
 0.4%
H
32.1
33.7
|
L
 15.0%
H
28.8
33.7
|
L
 12.1%
H
25.9
34.4
|
L
 15.7%
H
21.6
34.4
|
L
 108.0%
H
15.6
36.4
|
L
 3.2%
H
13.5
49.5
|
L
 -57.9%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
11.4
|
0.9
|
L
 3.5%
H
0.8
0.9
|
L
 9.9%
H
0.8
0.9
|
L
 -19.1%
H
0.7
1.2
|
L
 -2.2%
H
0.7
1.2
|
L
 58.9%
H
0.6
1.2
|
L
 -90.7%
H
0.5
13.4
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
28,936.9
|
196
|
L
 -0.2%
H
195.1
198.5
|
L
 1.2%
H
192.3
199.8
|
L
 0.8%
H
185.4
206.0
|
L
 2.2%
H
168.6
206.0
|
L
 51.0%
H
121.1
206.0
|
L
 -34.4%
H
110.0
319.8
|
L
 -26.7%
H
110.0
468.6
|
L
 -24.8%
H
110.0
468.6
|
| BioVie Inc |
|
10.7
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -6.6%
H
1.4
1.6
|
L
 -10.1%
H
1.3
1.8
|
L
 2.9%
H
1.2
1.8
|
L
 -86.4%
H
1.1
12.1
|
L
 -99.7%
H
1.1
645
|
L
 -99.9%
H
1.1
1910
|
L
 -99.9%
H
1.1
5625
|
| Biomea Fusion Inc |
|
99.8
|
1.4
|
L
H
1.4
1.4
|
L
 -2.8%
H
1.3
1.5
|
L
 -4.8%
H
1.2
1.7
|
L
 0.7%
H
1.1
2.2
|
L
 -4.2%
H
0.9
3.1
|
L
 -95.9%
H
0.9
43.7
|
L
 -92.0%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
11,073.3
|
57.3
|
L
 8.6%
H
53.5
57.5
|
L
 5.9%
H
52.2
57.5
|
L
 5.7%
H
49.3
57.5
|
L
 -7.2%
H
49.3
62.0
|
L
 -1.3%
H
49.3
66.3
|
L
 -34.3%
H
49.3
99.6
|
L
 -25.9%
H
49.3
117.8
|
L
 -35.7%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
14.2
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
H
1.2
1.3
|
L
 6.9%
H
1.1
1.4
|
L
 7.8%
H
1.1
1.5
|
L
 -66.2%
H
1.1
5.5
|
L
 -82.0%
H
0.1
11.6
|
L
 -98.0%
H
0.1
91.2
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
397.1
|
11.6
|
L
H
11.4
11.8
|
L
 2.9%
H
11.1
12
|
L
 -4.9%
H
10.5
12.7
|
L
 6.1%
H
10.0
14.3
|
L
 -24.7%
H
9.9
17.2
|
L
 195.7%
H
1.9
17.2
|
L
 -85.6%
H
1.9
86.2
|
L
 -97.2%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
10.1
|
5.3
|
L
 -0.9%
H
5.2
5.5
|
L
 6.1%
H
4.9
5.5
|
L
 10.3%
H
4.3
5.5
|
L
 16.2%
H
3.9
5.7
|
L
 -16.7%
H
3.9
7.4
|
L
 -84.6%
H
3.9
36.2
|
L
 -98.5%
H
3.9
385.7
|
L
H
3.9
861.4
|
| Bon Natural Life Ltd |
|
10.3
|
1.3
|
L
 2.4%
H
1.3
1.3
|
L
H
1.2
1.3
|
L
 -1.6%
H
1.2
1.3
|
L
 -25.3%
H
1.1
1.7
|
L
 -15.3%
H
1.1
3.4
|
L
 -99.3%
H
1.1
197.5
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
36.1
|
1.2
|
L
 -7.1%
H
1.2
1.3
|
L
 3.5%
H
1.1
1.4
|
L
 12.5%
H
1.1
1.4
|
L
 -29.9%
H
1.0
1.8
|
L
 -0.9%
H
1.0
8.1
|
L
 -93.8%
H
0.2
22.1
|
L
 -96.5%
H
0.2
39
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
21.4
|
1.2
|
L
 2.6%
H
1.2
1.3
|
L
 -3.2%
H
1.2
1.4
|
L
 64.4%
H
0.1
1.4
|
L
 79.1%
H
0.1
6.7
|
L
 1400%
H
0.1
6.7
|
L
 44.6%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
69.1
|
1.7
|
L
 -2.3%
H
1.7
1.8
|
L
 7.0%
H
1.4
1.8
|
L
 14.3%
H
1.2
1.8
|
L
 24.4%
H
1.2
1.9
|
L
 -3.5%
H
1.2
3.4
|
L
 63.1%
H
0.7
4
|
L
 -83.8%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
327.4
|
4.7
|
L
 0.4%
H
4.6
4.7
|
L
 3.1%
H
4.5
4.7
|
L
 -0.9%
H
4.3
5.2
|
L
 -18.2%
H
4.2
5.8
|
L
 -42.9%
H
4.2
9.4
|
L
 -80.5%
H
4.2
28.9
|
L
 -84.1%
H
4.2
62.1
|
L
H
4.2
62.1
|
| Biodexa Pharma PLC (ADR) |
|
2.6
|
3.5
|
L
 3.3%
H
3.3
3.5
|
L
 5.8%
H
3.2
3.5
|
L
 7.1%
H
3.0
5.1
|
L
 -35.7%
H
2.9
6.8
|
L
 -93.6%
H
2.9
66.5
|
L
 -100.0%
H
2.9
304375
|
L
 -100.0%
H
2.9
180500000
|
L
 -100.0%
H
2.9
10000000000
|
| BeiGene Ltd (ADR) |
|
30,671.0
|
287.9
|
L
 -0.9%
H
287.5
294.3
|
L
 -7.2%
H
287.5
312.0
|
L
 -1.0%
H
287.5
322.5
|
L
 -9.2%
H
271.5
328.4
|
L
 17.2%
H
239.3
385.2
|
L
 26.1%
H
127.0
385.2
|
L
 -19.7%
H
118.2
426.6
|
L
 956.2%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
16.4
|
3.8
|
L
 5.3%
H
3.5
4.0
|
L
 23.5%
H
3.0
4.0
|
L
 23.1%
H
2.5
4.0
|
L
 33.6%
H
2.2
4.0
|
L
 -28%
H
2.2
6.6
|
L
 -94.0%
H
0.1
101.2
|
L
 -96.7%
H
0.1
144.8
|
L
 -99.4%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
5,779.5
|
144.2
|
L
 -2.6%
H
139.6
151.4
|
L
 5.0%
H
134.0
151.4
|
L
 -6.7%
H
134.0
160.2
|
L
 -24.2%
H
134.0
188.7
|
L
 122.3%
H
56.1
200
|
L
 502.5%
H
11
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
28.7
|
5.3
|
L
 -0.9%
H
5.2
5.4
|
L
 -3.1%
H
5.1
5.5
|
L
 2.3%
H
4.4
5.5
|
L
 28.0%
H
3.8
5.5
|
L
 -20.0%
H
3.6
21.4
|
L
 143.6%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
24,264.2
|
96.0
|
L
 2.7%
H
94.0
97.4
|
L
 4.1%
H
90.9
97.4
|
L
 -5.5%
H
87.5
104.8
|
L
 -13.0%
H
79.5
113.3
|
L
 0.2%
H
79.5
124
|
L
 -8.0%
H
76.5
131.5
|
L
 -53.0%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.5
|
L
H
0.5
0.5
|
L
 -2.2%
H
0.4
0.5
|
L
 -36.6%
H
0.4
0.8
|
L
 -49.4%
H
0.4
1.1
|
L
 -83.5%
H
0.4
6.2
|
L
 -75.8%
H
0.4
6.2
|
L
 -98.5%
H
0.4
99
|
L
 -98.8%
H
0.4
620
|
| Cabaletta Bio Inc |
|
616.3
|
3.8
|
L
 0.3%
H
3.7
3.9
|
L
 3.6%
H
3.7
4.1
|
L
 36.0%
H
2.7
4.2
|
L
 13.9%
H
2.5
4.2
|
L
 102.1%
H
1.3
4.2
|
L
 -61.5%
H
1.0
26.4
|
L
 -66.7%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
13.0
|
0.8
|
L
 -5.8%
H
0.8
0.9
|
L
 30.2%
H
0.6
0.9
|
L
 46.4%
H
0.5
0.9
|
L
 57.7%
H
0.5
0.9
|
L
 -52.1%
H
0.5
7.2
|
L
 -76.9%
H
0.5
8.6
|
L
 -98.5%
H
0.5
98.8
|
L
H
0.5
530.3
|
| Capricor Therapeutics Inc |
|
1,735.0
|
30.0
|
L
 2.9%
H
29.5
30.5
|
L
 3.8%
H
28.8
30.5
|
L
 -7.7%
H
26.6
34.6
|
L
 7.3%
H
25.1
36.8
|
L
 202.9%
H
4.3
40.4
|
L
 580.9%
H
2.7
40.4
|
L
 690.5%
H
2.6
40.4
|
L
 -7.5%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
31.7
|
3.4
|
L
 -3.2%
H
3.3
3.5
|
L
 -5.3%
H
3.3
3.6
|
L
 10.5%
H
3.0
4.3
|
L
 -15.3%
H
2.8
4.3
|
L
 -88.1%
H
2.8
43.7
|
L
 -97.3%
H
2.8
160.2
|
L
 -99.3%
H
2.8
681.5
|
L
 -98.5%
H
2.8
1067.3
|
| Crescent Biopharma Inc |
|
-
|
20.7
|
L
 -3.8%
H
20.0
22.5
|
L
 -0.4%
H
19.7
22.5
|
L
 -1.4%
H
14.9
23.2
|
L
 70.8%
H
9.9
27.4
|
L
 127.7%
H
7.6
27.4
|
L
 496.8%
H
3.2
27.4
|
L
 98.2%
H
0.9
27.4
|
L
 -65.4%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
483.2
|
4.4
|
L
 19.4%
H
3.7
4.6
|
L
 22.8%
H
3.5
4.6
|
L
 70.7%
H
2.6
4.6
|
L
 61.9%
H
2.3
4.6
|
L
 249.6%
H
1.3
4.6
|
L
 30.4%
H
1.1
11.9
|
L
 -88.2%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
307.4
|
3.9
|
L
 0.5%
H
3.8
3.9
|
L
 5.5%
H
3.7
4.0
|
L
 -18.9%
H
3.6
5.1
|
L
 -23.6%
H
3.6
5.8
|
L
 -64.3%
H
3.6
14.7
|
L
 175.7%
H
1.3
14.7
|
L
 -53.5%
H
1.2
14.7
|
L
 -24.8%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
1,010.4
|
16.4
|
L
 7.0%
H
15
16.7
|
L
 18.8%
H
14
16.7
|
L
 27.9%
H
12.7
16.7
|
L
 6.1%
H
12.4
16.7
|
L
 90.3%
H
5.7
16.7
|
L
 62.5%
H
5.7
30.2
|
L
 -44.7%
H
5.7
37.7
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
248.8
|
2.6
|
L
 -5.4%
H
2.6
2.8
|
L
 -6.1%
H
2.6
2.8
|
L
 1.2%
H
2.5
3.1
|
L
 45.3%
H
1.9
3.2
|
L
 78.9%
H
1.3
3.2
|
L
 148.1%
H
0.5
3.2
|
L
 -65.8%
H
0.5
9.2
|
L
 -61.5%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
105.6
|
1.2
|
L
 -0.8%
H
1.1
1.2
|
L
 -6.4%
H
1.1
1.3
|
L
H
1.1
1.3
|
L
 8.3%
H
0.6
1.4
|
L
 391.7%
H
0.2
3.8
|
L
 -42.4%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
245.3
|
1.6
|
L
 -3.6%
H
1.6
1.7
|
L
 -1.2%
H
1.6
1.7
|
L
 -8.6%
H
1.5
2.1
|
L
 -4.8%
H
1.5
2.1
|
L
 103.9%
H
0.7
2.6
|
L
 -61.7%
H
0.7
5.6
|
L
 -87.9%
H
0.7
19.3
|
L
 -91.1%
H
0.7
32.0
|
| Cingulate Inc |
|
55.2
|
4.2
|
L
 -4.2%
H
3.8
4.4
|
L
 -6.9%
H
3.8
5.2
|
L
 -11.7%
H
3.8
5.5
|
L
 -33.7%
H
3.8
11.9
|
L
 6.1%
H
3.2
11.9
|
L
 352.2%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
83.8
|
6.6
|
L
 -2.1%
H
6.4
6.7
|
L
 -2.1%
H
6.4
6.8
|
L
 13.1%
H
5.7
8.7
|
L
 25.7%
H
4.5
8.7
|
L
 105.6%
H
3.2
13.5
|
L
 -65.4%
H
2.3
21.8
|
L
 -97.1%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
25.1
|
3.1
|
L
H
3.0
3.3
|
L
 -1.9%
H
3.0
3.3
|
L
 22.7%
H
2.5
4.7
|
L
 -3.1%
H
2.4
4.7
|
L
 -59.0%
H
2.4
20.6
|
L
 -93.1%
H
2.4
133.5
|
L
 -99.4%
H
2.4
552
|
L
 -100.0%
H
2.4
13740
|
| Clearmind Medicine Inc |
|
3.6
|
3.6
|
L
 46.1%
H
3.2
4.7
|
L
 58.4%
H
2.3
4.7
|
L
 -48.6%
H
2.1
7.4
|
L
 -68.3%
H
2.1
15.2
|
L
 -99.1%
H
2.1
524
|
L
 -100.0%
H
2.1
8160
|
L
 -100.0%
H
2.1
7884000
|
L
H
2.1
7884000
|
| Compass Therapeutics Inc |
|
428.6
|
2.4
|
L
 -1.2%
H
2.3
2.5
|
L
 15.0%
H
2.0
2.5
|
L
 42.5%
H
1.7
2.5
|
L
 -57.9%
H
1.6
6.8
|
L
 13.3%
H
1.6
6.9
|
L
 -15.3%
H
0.8
6.9
|
L
 -43.3%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
8.0
|
5.4
|
L
 11.3%
H
4.9
5.4
|
L
 0.4%
H
4.7
5.6
|
L
 140.7%
H
2.2
10.5
|
L
 74.9%
H
1.9
10.5
|
L
 -56.0%
H
1.9
13.0
|
L
 -100.0%
H
1.9
4470000
|
L
 -100.0%
H
1.9
120600000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
261.9
|
2.9
|
L
 0.7%
H
2.7
2.9
|
L
 9.6%
H
2.5
3.1
|
L
 21.8%
H
2.1
3.1
|
L
 26.7%
H
2.1
3.6
|
L
 391.4%
H
0.5
3.6
|
L
 190.8%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
15.4
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -2.6%
H
1.1
1.3
|
L
 -19.4%
H
1.1
1.5
|
L
 6.7%
H
1.0
2.0
|
L
 -34.5%
H
0.9
2.7
|
L
 -49.8%
H
0.9
3.3
|
L
 -91.7%
H
0.9
17.9
|
L
 -99.5%
H
0.9
234
|
| Co-Diagnostics Inc |
|
31.4
|
8.5
|
L
 -23.8%
H
8.1
13.5
|
L
 68.2%
H
6.3
13.5
|
L
 457.5%
H
1.3
13.5
|
L
 261.4%
H
1.3
13.5
|
L
 11.1%
H
1.3
46.5
|
L
 -73.4%
H
1.3
66.9
|
L
 -96.5%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
478.8
|
9.3
|
L
 4.5%
H
8.5
9.4
|
L
 3.7%
H
8.5
10.6
|
L
 -40.7%
H
8
16.7
|
L
 -22.7%
H
8
18.8
|
L
 1.8%
H
6.8
21.4
|
L
 -77.3%
H
2.3
41
|
L
 -5.4%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,973.5
|
35.0
|
L
 -1.2%
H
34.5
35.5
|
L
 7.0%
H
32.9
36.0
|
L
 -2.5%
H
30.9
37.5
|
L
 -10.0%
H
30.9
39.4
|
L
 542.7%
H
5.1
43.7
|
L
 206.9%
H
3.7
43.7
|
L
 303.7%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,090.1
|
33.6
|
L
 0.7%
H
33
33.6
|
L
 -1.4%
H
33
35.1
|
L
 -0.4%
H
33
40.5
|
L
 -19.3%
H
31.5
42.2
|
L
 15.3%
H
28.7
50.8
|
L
 54.2%
H
20.8
50.8
|
L
 40.7%
H
14.0
50.8
|
L
 102.5%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
7,459.9
|
69.5
|
L
 1.6%
H
68.0
69.6
|
L
 15.4%
H
59.0
69.9
|
L
 49.2%
H
45.7
69.9
|
L
 94.7%
H
31.8
69.9
|
L
 -10.4%
H
28.7
91
|
L
 201.5%
H
20.8
117.3
|
L
 221.7%
H
15.8
117.3
|
L
 1186.9%
H
5.0
117.3
|
| Cosmos Health Inc |
|
13.6
|
0.3
|
L
 -3.9%
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 -30.6%
H
0.3
0.4
|
L
 -35.9%
H
0.3
0.5
|
L
 -43.2%
H
0.3
1.3
|
L
 -92.2%
H
0.3
4
|
L
 -99.8%
H
0.3
194.3
|
L
 -99.8%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
92.1
|
6.2
|
L
 2.8%
H
6.0
6.3
|
L
 4.8%
H
5.7
6.6
|
L
 46.1%
H
4.1
6.6
|
L
 25%
H
2.7
6.6
|
L
 24.0%
H
1.9
6.6
|
L
 286.8%
H
1.0
7.3
|
L
 108.5%
H
1.0
7.5
|
L
 35.5%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
3,822.0
|
31.2
|
L
 -0.2%
H
31.2
31.3
|
L
 -0.1%
H
31.2
31.3
|
L
 10.5%
H
27.7
31.4
|
L
 35.3%
H
22.2
32.6
|
L
 25.1%
H
19.1
32.6
|
L
 170.4%
H
11.1
32.6
|
L
 464.7%
H
4.8
32.6
|
L
 5019.7%
H
0.6
32.6
|
| Corbus Pharma Holdings Inc |
|
146.6
|
7.9
|
L
 3.5%
H
7.7
8.1
|
L
 -30.3%
H
7.5
10
|
L
 -19.5%
H
7.5
12.9
|
L
 -7.7%
H
7.5
12.9
|
L
 6.6%
H
6.7
20.6
|
L
 -10.8%
H
3.0
61.9
|
L
 -87.8%
H
2.1
68.7
|
L
 -91.2%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
234.1
|
2.4
|
L
 2.2%
H
2.3
2.4
|
L
 12.4%
H
2.1
2.4
|
L
 22.9%
H
1.8
2.4
|
L
 24.2%
H
1.7
2.4
|
L
 122.6%
H
1.0
3.5
|
L
 -45.6%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
140.6
|
1.2
|
L
 -4.7%
H
1.2
1.3
|
L
 -7.6%
H
1.2
1.4
|
L
 -6.9%
H
1.2
1.4
|
L
 19.6%
H
0.9
1.7
|
L
 -2.4%
H
0.9
1.7
|
L
 82.1%
H
0.6
3.1
|
L
 -63.1%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
22.2
|
0.6
|
L
 9.6%
H
0.5
0.6
|
L
 14%
H
0.5
0.6
|
L
 1.8%
H
0.5
0.6
|
L
 -50%
H
0.5
1.1
|
L
 -76.8%
H
0.5
3.1
|
L
 -96.4%
H
0.5
18
|
L
 -99.8%
H
0.5
312
|
L
 -99.7%
H
0.5
372
|
| CorMedix Inc |
|
662.1
|
8.4
|
L
 0.2%
H
8.3
8.5
|
L
 5.8%
H
8.0
8.6
|
L
 12.8%
H
7.4
8.9
|
L
 18.4%
H
6.1
8.9
|
L
 -30.5%
H
6.1
17.4
|
L
 75.1%
H
2.6
17.4
|
L
 16.7%
H
2.6
17.4
|
L
 -40.4%
H
0.9
18.8
|
| Crinetics Pharma Inc |
|
3,748.4
|
35.6
|
L
 -1.3%
H
34.8
36.2
|
L
 -3.4%
H
34.8
37.4
|
L
 -7.5%
H
33.9
43.6
|
L
 -13.5%
H
33.1
43.6
|
L
 16.5%
H
25.8
58.0
|
L
 61.2%
H
15.8
62.5
|
L
 102.6%
H
15.2
62.5
|
L
H
10.6
62.5
|
| Cronos Grp Inc |
|
1,061.2
|
2.8
|
L
H
2.8
2.9
|
L
 3.7%
H
2.7
2.9
|
L
 10.1%
H
2.5
2.9
|
L
 6.4%
H
2.4
3.3
|
L
 43.4%
H
1.8
3.4
|
L
 62.3%
H
1.6
3.4
|
L
 -68.5%
H
1.6
9.4
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
5,418.5
|
56.2
|
L
 -0.4%
H
54.3
56.4
|
L
 11.6%
H
50.2
57.2
|
L
 10.8%
H
46.9
57.2
|
L
 -6.6%
H
44.1
61
|
L
 54.8%
H
36.1
78.5
|
L
 -13.1%
H
30.0
91.1
|
L
 -52.5%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
1,043.6
|
12.4
|
L
 -0.7%
H
12.0
12.8
|
L
 -1.6%
H
12.0
14
|
L
 -13.9%
H
11.4
16.9
|
L
 -32.0%
H
11.4
19.7
|
L
 228.3%
H
3.6
27.0
|
L
 301.6%
H
1.1
27.0
|
L
 352.9%
H
0.6
27.0
|
L
 -13.9%
H
0.6
27.0
|
| Champions Oncology Inc |
|
81.1
|
5.8
|
L
 -0.2%
H
5.8
5.9
|
L
 -2.8%
H
5.7
6.2
|
L
 -0.2%
H
5.7
6.4
|
L
 -2.0%
H
5.5
6.4
|
L
 -0.5%
H
5.5
9.6
|
L
 18.0%
H
3.6
12.0
|
L
 -37.9%
H
3.6
12.0
|
L
 76.4%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
783.7
|
3.6
|
L
 -3.0%
H
3.5
3.7
|
L
 -4.3%
H
3.5
3.9
|
L
 -11.1%
H
3.4
4.4
|
L
 -33.0%
H
3.4
8.2
|
L
 35.9%
H
1.7
8.2
|
L
 114.3%
H
0.4
8.2
|
L
 -49.7%
H
0.4
8.2
|
L
 -66.1%
H
0.4
35
|
| Cue Biopharma Inc |
|
88.6
|
21.9
|
L
 -3.3%
H
20.8
23.0
|
L
 2%
H
19.8
23.4
|
L
 68.5%
H
13.2
41.4
|
L
 160.7%
H
5.0
41.4
|
L
 14.4%
H
5.0
41.4
|
L
 -82.2%
H
5.0
146.7
|
L
 -94.9%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
15.3
|
5.0
|
L
 -0.8%
H
4.9
5.2
|
L
 -4.4%
H
4.8
5.6
|
L
 -11.3%
H
4.8
7.3
|
L
 -41.6%
H
4.2
9.0
|
L
 -62.8%
H
4.2
16.0
|
L
 264.7%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
6.1
|
1.1
|
L
 4.8%
H
1.0
1.1
|
L
 13.4%
H
0.9
1.1
|
L
 18.3%
H
0.9
1.2
|
L
 12.2%
H
0.7
1.3
|
L
 -95.5%
H
0.7
26.1
|
L
 -100.0%
H
0.7
3168
|
L
 -100.0%
H
0.7
26820
|
L
 -100.0%
H
0.7
784800
|
| Cyclerion Therapeutics Inc |
|
13.6
|
3.2
|
L
 -0.9%
H
3.2
3.3
|
L
 -0.9%
H
3.0
3.3
|
L
 -5.1%
H
2.9
3.4
|
L
 133.3%
H
1.3
8.5
|
L
 12.1%
H
1.0
8.5
|
L
 -27.4%
H
1.0
8.5
|
L
 -95.1%
H
1.0
97.2
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
10,421.8
|
76.8
|
L
 -0.1%
H
75.7
77.1
|
L
 -0.2%
H
75
78.9
|
L
 28.8%
H
59.7
80.2
|
L
 23.4%
H
58.4
80.2
|
L
 147.5%
H
30.6
80.2
|
L
 102.2%
H
26.0
110
|
L
 251.6%
H
17.7
110
|
L
 846.5%
H
5.8
110
|
| Cellectis (ADR) |
|
354.2
|
3.5
|
L
 -3.0%
H
3.5
3.6
|
L
 0.6%
H
3.5
3.8
|
L
 -5.6%
H
3.5
4.2
|
L
 -9.3%
H
3.0
4.6
|
L
 141.1%
H
1.3
5.5
|
L
 85.3%
H
1.0
5.5
|
L
 -77.5%
H
1.0
16.5
|
L
 -88.7%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
14.4
|
2
|
L
 -3.4%
H
2.0
2.1
|
L
 -1.0%
H
1.9
2.1
|
L
 37.0%
H
1.5
2.1
|
L
 7.5%
H
1.5
2.2
|
L
 -62.1%
H
1.4
5.5
|
L
 -68.4%
H
1.4
10.2
|
L
 -97.2%
H
1.4
111.7
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,762.4
|
13.1
|
L
 9.6%
H
11.8
13.1
|
L
 10.6%
H
11.4
13.1
|
L
 55.9%
H
8.2
13.1
|
L
 89.3%
H
4.9
13.1
|
L
 213.9%
H
2.3
13.1
|
L
 75.1%
H
2.3
13.1
|
L
 -62.4%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Centessa Pharma PLC (ADR) |
|
6,152.0
|
39.8
|
L
 -0.1%
H
39.7
39.8
|
L
 0.0%
H
39.7
39.8
|
L
 0.8%
H
39.4
39.9
|
L
 48.0%
H
25.1
40.3
|
L
 194.3%
H
11.0
40.3
|
L
 770.0%
H
4.3
40.3
|
L
 82.8%
H
2.9
40.3
|
L
H
2.9
40.3
|
| Connect Biopharma Holdings Ltd (ADR) |
|
138.7
|
2.5
|
L
 4.6%
H
2.3
2.5
|
L
 6.0%
H
2.3
2.7
|
L
 -1.6%
H
2.2
2.7
|
L
 0.8%
H
2.2
3.8
|
L
 196.4%
H
0.7
3.8
|
L
 124.3%
H
0.5
3.8
|
L
 -83.3%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
33.4
|
2.2
|
L
 -2.2%
H
2.2
2.3
|
L
 -5.9%
H
2.2
2.5
|
L
 6.2%
H
1.9
3.8
|
L
 31.2%
H
1.3
3.8
|
L
 -24.9%
H
1.3
9.2
|
L
 -81.6%
H
0.3
12.2
|
L
 -85.5%
H
0.3
30.1
|
L
 -99.2%
H
0.3
429.6
|
| Journey Medical Corp |
|
173.7
|
6.3
|
L
 1.8%
H
6.0
6.5
|
L
 5.9%
H
5.8
6.5
|
L
 26.2%
H
4.8
6.7
|
L
 -22.8%
H
4.3
8.5
|
L
 -21.7%
H
4.3
9.6
|
L
 408.9%
H
1.1
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
3.1
|
L
 -1.0%
H
3.0
3.3
|
L
 1.6%
H
3.0
3.3
|
L
 -14.8%
H
2.8
4.2
|
L
 -22.1%
H
2.8
5.1
|
L
 -56.9%
H
2.8
13.1
|
L
 -47.3%
H
2.8
14.4
|
L
 -94.1%
H
2.8
64.1
|
L
 -100.0%
H
2.8
17437.5
|
| DiaMedica Therapeutics Inc |
|
322.8
|
6.0
|
L
 -2.8%
H
6.0
6.4
|
L
 1.4%
H
5.9
6.4
|
L
 0.5%
H
5.5
6.6
|
L
 -24.7%
H
5.5
8.1
|
L
 45.7%
H
3.5
10.4
|
L
 113.2%
H
1.9
10.4
|
L
 -19.2%
H
1.1
10.4
|
L
 81.5%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,339.3
|
21.0
|
L
 0.4%
H
20.8
21.2
|
L
 12.9%
H
18.6
21.2
|
L
 13.1%
H
17.7
21.2
|
L
 -0.7%
H
17.7
23.5
|
L
 58.9%
H
12.6
23.8
|
L
 -28.1%
H
10.6
33.3
|
L
 -66.9%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
83.7
|
3.7
|
L
 7.3%
H
3.6
3.8
|
L
 14.2%
H
3.1
3.8
|
L
 33.1%
H
2.8
4.6
|
L
 22.1%
H
2.7
4.6
|
L
 -16.3%
H
2.7
8.4
|
L
 42.9%
H
0.8
13.6
|
L
 -79.7%
H
0.8
20.6
|
L
 -97.6%
H
0.8
308.4
|
| DarioHealth Corp |
|
56.7
|
7.8
|
L
 3.1%
H
7.4
7.8
|
L
 -1.4%
H
7.3
8.1
|
L
 3.3%
H
7.1
8.8
|
L
 -35.3%
H
6.2
11.6
|
L
 -45.8%
H
5.9
17.7
|
L
 -89.9%
H
5.9
91.6
|
L
 -97.6%
H
5.9
476
|
L
 -99.6%
H
5.9
2200
|
| Dermata Therapeutics Inc |
|
5.2
|
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 3.2%
H
1.2
1.4
|
L
 3.2%
H
1.2
1.4
|
L
 8.3%
H
1.1
1.8
|
L
 80.6%
H
0.6
7.1
|
L
 -14.5%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
864.1
|
88.1
|
L
 -1.6%
H
87.4
90.7
|
L
 5.5%
H
83.3
92
|
L
 -1.2%
H
72.4
92
|
L
 5.1%
H
66.2
92.4
|
L
 239.4%
H
23.2
123.8
|
L
 2687.0%
H
0.9
123.8
|
L
 277.7%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
654.5
|
10.5
|
L
 -2.4%
H
10.3
10.8
|
L
 -4.5%
H
10.3
11.9
|
L
 -33.6%
H
10
17.0
|
L
 0.4%
H
9.7
17.3
|
L
 181.0%
H
3.3
17.3
|
L
 75.0%
H
1.9
17.3
|
L
 -60%
H
1.9
28.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
179.8
|
7.0
|
L
 0.7%
H
6.7
7.1
|
L
 -3.6%
H
6.7
8.2
|
L
 1.0%
H
6.5
8.6
|
L
 66.0%
H
4.0
8.6
|
L
 44.3%
H
3.5
8.8
|
L
 729.8%
H
0.3
19.4
|
L
 -33.8%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,195.5
|
19.3
|
L
 4.2%
H
18.7
19.6
|
L
 11.3%
H
17.5
19.6
|
L
 11.0%
H
15.9
19.6
|
L
 23.8%
H
14
21.4
|
L
 61.6%
H
8.1
25
|
L
 52.9%
H
6.4
47.5
|
L
 1.2%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
1,130.5
|
19.1
|
L
 0.6%
H
18.6
19.8
|
L
 5.1%
H
18.1
19.8
|
L
 -5.9%
H
18.0
21.4
|
L
 -9%
H
18.0
24.1
|
L
 128.7%
H
7.5
26.2
|
L
 3.2%
H
0.5
26.2
|
L
 -67.4%
H
0.5
64.7
|
L
 -94.1%
H
0.5
505.7
|
| Editas Medicine Inc |
|
531.0
|
3.5
|
L
 0.9%
H
3.2
3.5
|
L
 25.4%
H
2.4
3.9
|
L
 22.7%
H
2.4
3.9
|
L
 57.3%
H
1.8
3.9
|
L
 101.2%
H
1.7
4.5
|
L
 -61.4%
H
0.9
11.9
|
L
 -89.8%
H
0.9
73.0
|
L
 -90.2%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
64.2
|
7.2
|
L
 -8.1%
H
7.2
7.8
|
L
 -31.0%
H
7.2
11.4
|
L
 -54.6%
H
7.2
20.3
|
L
 228.2%
H
2
20.3
|
L
 268.4%
H
0.7
20.3
|
L
 14.6%
H
0.7
20.3
|
L
 -83.5%
H
0.7
84
|
L
 -99.2%
H
0.7
1669.9
|
| Eledon Pharma Inc |
|
294.1
|
3.8
|
L
 -1.6%
H
3.8
3.9
|
L
 -2.1%
H
3.8
4.0
|
L
 14.1%
H
3.4
4.1
|
L
 45.4%
H
2.4
4.2
|
L
 27%
H
1.4
4.6
|
L
 117.7%
H
1.1
5.4
|
L
 -60.0%
H
1.1
9.8
|
L
 -99.7%
H
1.1
1228.0
|
| Elicio Therapeutics Inc |
|
218.3
|
11.4
|
L
 7.8%
H
10.4
11.5
|
L
 15.0%
H
10.0
11.5
|
L
 10.9%
H
9.1
12.8
|
L
 -11.9%
H
9.1
14.9
|
L
 58.2%
H
6.9
14.9
|
L
 15.6%
H
3.0
24.4
|
L
 -92.6%
H
3.0
159.1
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
2,410.0
|
39.6
|
L
 -2.7%
H
39.0
40.9
|
L
 -4.7%
H
39.0
43.0
|
L
 -6.7%
H
38.6
45.1
|
L
 33.3%
H
26.7
48.5
|
L
 122.7%
H
14.8
48.5
|
L
 118.7%
H
9.8
48.5
|
L
 36.1%
H
3.9
48.5
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
627.6
|
11.0
|
L
 -3.4%
H
10.9
11.6
|
L
 -0.4%
H
10.9
12.2
|
L
 24.8%
H
7.9
12.5
|
L
 53.3%
H
5.9
12.5
|
L
 828.8%
H
1.2
12.5
|
L
 260.5%
H
1.1
12.5
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
195.2
|
0.8
|
L
 6.6%
H
0.8
0.8
|
L
 12.5%
H
0.7
0.8
|
L
 1.3%
H
0.7
0.9
|
L
 -29.6%
H
0.7
1.3
|
L
 -13.8%
H
0.7
2.1
|
L
 -69.2%
H
0.7
4.6
|
L
 -91.4%
H
0.7
14.0
|
L
 -99.0%
H
0.7
88
|
| Enochian Biosciences Inc |
|
-
|
3.1
|
L
 1.3%
H
2.9
3.1
|
L
 36.3%
H
2.0
3.2
|
L
 833.3%
H
0.2
3.2
|
L
 732.4%
H
0.2
3.2
|
L
 893.6%
H
0.1
3.2
|
L
 227.7%
H
0.1
3.2
|
L
 -24.3%
H
0.1
13.8
|
L
 23.2%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
4.1
|
0.3
|
L
 -6.7%
H
0.3
0.3
|
L
 -12.5%
H
0.3
0.3
|
L
 -22.2%
H
0.2
0.4
|
L
 -54.8%
H
0.2
0.8
|
L
 -87.4%
H
0.2
2.8
|
L
 -88.1%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
382.7
|
13.2
|
L
 -0.5%
H
13.0
13.3
|
L
 -5.7%
H
13.0
14.1
|
L
 -5.1%
H
13.0
15.9
|
L
 -8.0%
H
11.8
15.9
|
L
 121.9%
H
5.9
17.2
|
L
 -44.7%
H
4.1
26.9
|
L
 -73.0%
H
4.1
102
|
L
 -46.0%
H
4.1
127.8
|
| Entera Bio Ltd |
|
66.5
|
1.4
|
L
 10.7%
H
1.2
1.4
|
L
 8.9%
H
1.2
1.4
|
L
 20.5%
H
1.1
1.4
|
L
 -2.9%
H
0.9
1.6
|
L
 -26.6%
H
0.9
3.2
|
L
 75.3%
H
0.5
3.4
|
L
 -58.2%
H
0.5
8.7
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
8.5
|
2.3
|
L
 -0.9%
H
2.2
2.4
|
L
 4.1%
H
2.1
2.4
|
L
 -55.4%
H
1.9
4.6
|
L
 -2.1%
H
1.7
7.9
|
L
 -83.8%
H
1.7
17.6
|
L
 -99.7%
H
1.7
860.4
|
L
 -100.0%
H
1.7
33660
|
L
 -100.0%
H
1.7
12150000
|
| Evolus Inc |
|
432.0
|
6.6
|
L
 -0.2%
H
6.5
6.6
|
L
 7.7%
H
6.0
6.8
|
L
 26.6%
H
5.1
6.8
|
L
 52.6%
H
3.9
6.8
|
L
 -28.6%
H
3.9
10.6
|
L
 -27.1%
H
3.9
17.8
|
L
 -39.4%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
183.4
|
2.9
|
L
 2.1%
H
2.8
3
|
L
 28.3%
H
2.2
3.1
|
L
 39.4%
H
1.8
3.1
|
L
 59.3%
H
1.6
3.1
|
L
 643.6%
H
0.3
3.1
|
L
 353.1%
H
0.3
3.3
|
L
 -55.8%
H
0.3
7.8
|
L
H
0.3
27.1
|
| Erasca Inc |
|
3,993.0
|
12.8
|
L
 5.3%
H
12
13.1
|
L
 14.2%
H
10.9
13.1
|
L
 40.9%
H
8.9
13.1
|
L
 -6%
H
8.7
24.3
|
L
 817.1%
H
1.2
24.3
|
L
 390.1%
H
1.0
24.3
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
805.8
|
3.1
|
L
H
3.1
3.1
|
L
H
3.1
3.1
|
L
 63.9%
H
1.9
3.2
|
L
 -6.6%
H
1.8
3.4
|
L
 268.2%
H
0.9
4.2
|
L
 123.6%
H
0.7
4.2
|
L
 -84.3%
H
0.7
26.8
|
L
 -80.9%
H
0.7
82.7
|
| Eton Pharma Inc |
|
834.1
|
30.5
|
L
 -4.4%
H
30.1
32.0
|
L
 -6.6%
H
30.1
32.9
|
L
 29.1%
H
23.3
35.7
|
L
 79.2%
H
16.1
35.7
|
L
 61.2%
H
13.1
35.7
|
L
 688.9%
H
2.4
35.7
|
L
 331.3%
H
2.0
35.7
|
L
H
2.0
35.7
|
| Edgewise Therapeutics Inc |
|
3,675.4
|
34.2
|
L
 2.6%
H
33.1
34.6
|
L
 4.5%
H
31.7
34.6
|
L
 12.2%
H
30.1
40.0
|
L
 12.2%
H
26.8
40.0
|
L
 139.2%
H
12.2
40.0
|
L
 250.4%
H
5.1
40.0
|
L
 18.3%
H
5.1
40.0
|
L
H
5.1
40.5
|
| Exelixis Inc |
|
12,688.4
|
50.5
|
L
 -1.9%
H
50.4
51.7
|
L
 0.7%
H
49.5
53.0
|
L
 13.0%
H
43.5
53.0
|
L
 14.6%
H
39.7
53.0
|
L
 17.3%
H
33.8
53.0
|
L
 165.5%
H
18.6
53.0
|
L
 123.9%
H
14.9
53.0
|
L
 696.2%
H
6.4
53.0
|
| Hyperion DeFi Inc |
|
53.1
|
3.5
|
L
 1.7%
H
3.3
3.6
|
L
 -3.3%
H
3.3
3.9
|
L
 -11.6%
H
3.1
4.8
|
L
 24.1%
H
2.8
5.0
|
L
 109.6%
H
1.6
17.2
|
L
 -98.5%
H
0.0
253.7
|
L
 -99.1%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,138.6
|
13.6
|
L
 0.6%
H
13.5
14.0
|
L
 5.0%
H
12.7
14.0
|
L
 5.6%
H
11.4
14.7
|
L
 -22.7%
H
11.4
18.9
|
L
 87.6%
H
7.1
19.1
|
L
 132.5%
H
3.9
31.0
|
L
 38.1%
H
2.2
31.0
|
L
 -64.7%
H
2.2
42.5
|
| Evaxion Biotech A/S (ADR) |
|
33.4
|
4
|
L
 -2.4%
H
4
4.1
|
L
 -2.0%
H
4.0
4.2
|
L
 -6.1%
H
3.9
4.8
|
L
 26.6%
H
3.0
4.8
|
L
 62.6%
H
2.1
12.2
|
L
 -74.4%
H
0.8
18.5
|
L
 -94.1%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE (ADR) |
|
1,090.4
|
3.1
|
L
 3.7%
H
3.0
3.1
|
L
 1.3%
H
2.9
3.1
|
L
 4.4%
H
2.6
3.3
|
L
 -9.7%
H
2.3
3.4
|
L
 -22.7%
H
2.3
4.4
|
L
 -71.2%
H
2.3
13.5
|
L
 -84.7%
H
2.3
26.6
|
L
 39.5%
H
2.0
26.6
|
| Fate Therapeutics Inc |
|
331.0
|
2.8
|
L
 8.0%
H
2.6
2.9
|
L
 26.2%
H
2.1
2.9
|
L
 129.0%
H
1.2
2.9
|
L
 91.9%
H
1.0
2.9
|
L
 134.7%
H
0.9
2.9
|
L
 -42.7%
H
0.7
8.8
|
L
 -96.3%
H
0.7
97.4
|
L
 82.1%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
93.0
|
2.8
|
L
 -0.4%
H
2.7
2.8
|
L
 2.2%
H
2.7
2.9
|
L
 26.1%
H
2.2
2.9
|
L
 -18.1%
H
2.2
3.5
|
L
 48.2%
H
1.7
4.5
|
L
 -65.4%
H
1.2
10.7
|
L
 -95.4%
H
1.2
67.4
|
L
 -93.4%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
390.5
|
19.1
|
L
 -8.2%
H
18.6
20.7
|
L
 -11.7%
H
18.6
23.1
|
L
 -32.0%
H
18.6
30.4
|
L
 -36.9%
H
18.6
35.8
|
L
 124.4%
H
7.8
35.8
|
L
 -25.2%
H
4.1
35.8
|
L
 -97.9%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
518.1
|
9.9
|
L
 10.5%
H
8.9
10
|
L
 15.2%
H
8.6
10
|
L
 12.5%
H
8.1
11.2
|
L
 2.6%
H
8.0
11.2
|
L
 173.8%
H
3.6
12.3
|
L
 -46.1%
H
2.2
36.3
|
L
 -62.7%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
344.9
|
9.9
|
L
 0.4%
H
9.7
10.1
|
L
H
9.7
10.3
|
L
 58.6%
H
6.2
10.5
|
L
 17.0%
H
5.7
10.5
|
L
 22.3%
H
5.7
10.5
|
L
 34.4%
H
4.0
11.9
|
L
 34.7%
H
3.8
11.9
|
L
 302.0%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
27.9
|
6.9
|
L
 -1.7%
H
6.9
7.1
|
L
 -1.3%
H
6.9
7.2
|
L
 -2.1%
H
6.8
7.3
|
L
 -0.4%
H
6.3
7.7
|
L
 -4.2%
H
4.9
12.6
|
L
 -98.4%
H
4.5
486.8
|
L
 -98.7%
H
4.5
753.1
|
L
 -98.5%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
251.3
|
4.3
|
L
 0.2%
H
4.2
4.3
|
L
 1.4%
H
4.1
4.6
|
L
 -10.1%
H
3.6
4.9
|
L
 -24.7%
H
3.6
5.8
|
L
 4.9%
H
3.3
7.0
|
L
 -33.3%
H
2.7
10.2
|
L
 -58.9%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
187.4
|
11.1
|
L
 7.2%
H
10.4
12.2
|
L
 90.5%
H
5.8
13.2
|
L
 100.9%
H
5.0
13.2
|
L
 142.3%
H
4.2
13.2
|
L
 538.7%
H
1.3
13.2
|
L
 -36.7%
H
1.3
53.8
|
L
 -90.8%
H
1.3
160.2
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
11.3
|
4.6
|
L
 1.8%
H
4.4
4.7
|
L
 8.4%
H
4.0
4.7
|
L
 -25.2%
H
3.7
6.5
|
L
 -42.7%
H
3.7
9.7
|
L
 -82.2%
H
3.7
47
|
L
 -97.4%
H
3.7
213.7
|
L
 -99.9%
H
3.7
16731
|
L
H
3.7
16731
|
| Frequency Therapeutics Inc |
|
-
|
13.4
|
L
 0.1%
H
12.6
13.5
|
L
 15.5%
H
11.7
14.0
|
L
 6.3%
H
9.1
14.0
|
L
 10.6%
H
9.1
15.6
|
L
 17.4%
H
5.2
55.9
|
L
 -23.9%
H
5.2
55.9
|
L
 -97.0%
H
5.2
545
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
461.1
|
6.9
|
L
 1.5%
H
6.7
7.1
|
L
 5.3%
H
6.5
7.1
|
L
 -3.2%
H
5.9
7.6
|
L
 -17.4%
H
5.9
8.6
|
L
 0.6%
H
5.9
15.7
|
L
 139.4%
H
2.3
15.7
|
L
 -22.5%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
8.8
|
5.6
|
L
 13.3%
H
5.1
5.7
|
L
 15.9%
H
4.5
5.7
|
L
 162.2%
H
2.1
5.7
|
L
 143.9%
H
1.9
5.7
|
L
 1204.7%
H
0.4
5.8
|
L
 -85.8%
H
0.4
60
|
L
 -100.0%
H
0.4
40741.3
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
166.0
|
2.5
|
L
 -2.0%
H
2.4
2.6
|
L
 0.8%
H
2.4
3.1
|
L
 12%
H
2.0
3.1
|
L
 -15.4%
H
2.0
3.5
|
L
 92.4%
H
1.3
7.1
|
L
 56.5%
H
0.7
7.1
|
L
 -36.5%
H
0.7
7.1
|
L
 70.3%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
83.2
|
2.0
|
L
 -3.5%
H
1.9
2.0
|
L
 9.6%
H
1.8
2.1
|
L
 10.8%
H
1.5
2.1
|
L
 -25.3%
H
1.5
3.1
|
L
 10.2%
H
1.4
4.3
|
L
 -57.5%
H
0.9
5.3
|
L
 -81.6%
H
0.9
10.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
13.8
|
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 3.5%
H
1.1
1.2
|
L
 18.2%
H
0.7
1.4
|
L
 8.3%
H
0.7
1.4
|
L
 -49.6%
H
0.7
3.7
|
L
 -57.9%
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
801.9
|
1.3
|
L
H
1.2
1.3
|
L
 -2.3%
H
1.2
1.3
|
L
 -17.2%
H
1.2
1.7
|
L
 -25.6%
H
1.2
1.8
|
L
 -17.8%
H
1.0
2.0
|
L
 -62.3%
H
1.0
5.3
|
L
 -9.4%
H
1.0
5.3
|
L
 -56.1%
H
0.8
7.0
|
| GH Research PLC |
|
1,645.9
|
24.0
|
L
 7.2%
H
22.0
24.3
|
L
 8.5%
H
21.8
24.3
|
L
 25.2%
H
19.2
24.3
|
L
 61.6%
H
12.8
24.7
|
L
 99.4%
H
11.0
24.7
|
L
 120.1%
H
5.1
24.7
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
166,904.2
|
134.4
|
L
 -1.3%
H
133.5
137.2
|
L
 0.1%
H
132.6
137.2
|
L
 4.3%
H
128.0
137.5
|
L
 -9.8%
H
127.6
150.8
|
L
 22.1%
H
104.5
157.3
|
L
 76.1%
H
62.1
157.3
|
L
 103.3%
H
57.2
157.3
|
L
 56.6%
H
56.6
157.3
|
| Galmed Pharma Ltd |
|
4.9
|
0.8
|
L
 10.3%
H
0.7
0.8
|
L
 29.3%
H
0.6
0.8
|
L
 33.9%
H
0.5
0.8
|
L
 23.0%
H
0.4
1.3
|
L
 -47.6%
H
0.4
2.3
|
L
 -98.5%
H
0.2
65.6
|
L
 -99.8%
H
0.2
734.4
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
362.7
|
26.2
|
L
 -9.7%
H
26
29.4
|
L
 -5.3%
H
26
29.8
|
L
 21.2%
H
21.4
29.8
|
L
 -5.6%
H
20.5
30.3
|
L
 165.8%
H
7.8
34.1
|
L
 140.0%
H
7.6
34.1
|
L
 -29.4%
H
6.8
49.0
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,531.4
|
24.9
|
L
 0.2%
H
24.6
26.0
|
L
 -1.7%
H
24.6
26.5
|
L
 4.0%
H
22.0
27.0
|
L
 -15.9%
H
16.5
30.9
|
L
 710.4%
H
2.5
38.3
|
L
 981.7%
H
0.5
38.3
|
L
 368.5%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,665.1
|
19.7
|
L
 1.7%
H
19.2
20.4
|
L
 4.8%
H
18.8
20.4
|
L
 5.3%
H
17.4
21.3
|
L
 11.0%
H
14.2
21.6
|
L
 371.5%
H
4.1
25.8
|
L
 202.3%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
1,332.6
|
20.7
|
L
 -3.8%
H
20.0
22.5
|
L
 -0.4%
H
19.7
22.5
|
L
 -1.4%
H
14.9
23.2
|
L
 70.8%
H
9.9
27.4
|
L
 -1.7%
H
8.7
27.4
|
L
 -88.5%
H
8.7
353
|
L
 -91.9%
H
8.7
416
|
L
 -97.6%
H
8.7
2605
|
| Genelux Corp |
|
136.8
|
3.1
|
L
 -0.7%
H
3.0
3.1
|
L
 4.5%
H
2.9
3.2
|
L
 22%
H
2.5
3.3
|
L
 2.4%
H
2.3
3.3
|
L
 26.0%
H
2.3
8.5
|
L
 -87.8%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
8.3
|
0.8
|
L
 -2.5%
H
0.8
0.8
|
L
 -4.9%
H
0.8
0.8
|
L
 -10.3%
H
0.7
1.0
|
L
 -61%
H
0.7
2.1
|
L
 136.4%
H
0.1
13.0
|
L
 -2.5%
H
0.1
13.0
|
L
 -79.1%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
54.0
|
0.2
|
L
 9.5%
H
0.2
0.2
|
L
 9.5%
H
0.2
0.2
|
L
 -34.3%
H
0.2
0.4
|
L
 -45.2%
H
0.2
0.6
|
L
 -79.3%
H
0.2
3.9
|
L
 -81.7%
H
0.2
3.9
|
L
 -97.3%
H
0.2
15.2
|
L
H
0.2
27.2
|
| Geovax Labs Inc |
|
10.7
|
2.1
|
L
 -14.2%
H
2.0
2.3
|
L
 -43.4%
H
2.0
3.6
|
L
 96.2%
H
1
4.4
|
L
 28.8%
H
1.0
4.4
|
L
 -91.9%
H
1.0
34.8
|
L
 -99.1%
H
1.0
276.8
|
L
 -99.9%
H
1.0
2812.5
|
L
 -100.0%
H
1.0
379518072.3
|
| Graphite Bio Inc |
|
453.1
|
7.8
|
L
 -2.6%
H
7.8
8.5
|
L
 3.1%
H
7.5
8.5
|
L
 -14.0%
H
6.6
10.6
|
L
 -42.3%
H
6.6
15.0
|
L
 -73.4%
H
6.6
50.4
|
L
 -94.3%
H
6.6
413
|
L
H
6.6
1666
|
L
H
6.6
1666
|
| GT Biopharma Inc |
|
17.3
|
0.5
|
L
 9.1%
H
0.4
0.5
|
L
 9.1%
H
0.4
0.5
|
L
 77.8%
H
0.3
0.5
|
L
H
0.3
0.5
|
L
 -81.4%
H
0.3
3.9
|
L
 92%
H
0.2
10.7
|
L
 -97.2%
H
0.2
19.7
|
L
 -100.0%
H
0.2
2295
|
| Galapagos NV (ADR) |
|
1,868.2
|
28.4
|
L
 0.1%
H
28.2
28.7
|
L
 3.1%
H
27.2
28.7
|
L
 1.8%
H
26.4
29.7
|
L
 -15.8%
H
26.4
34.4
|
L
 -1.4%
H
26.4
37.8
|
L
 -32.7%
H
22.4
44.3
|
L
 -62.8%
H
22.4
81.1
|
L
 -51.6%
H
22.4
274.0
|
| Genmab (ADR) |
|
16,164.9
|
26.3
|
L
 -2.6%
H
26.3
27.1
|
L
 -2.0%
H
26.2
27.1
|
L
 0.8%
H
25.3
28.3
|
L
 -10.6%
H
25.0
29.9
|
L
 25.7%
H
20.2
35.4
|
L
 -33.0%
H
17.2
42.7
|
L
 -35.2%
H
17.2
49.1
|
L
 49.3%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
24.3
|
1.0
|
L
 14.4%
H
0.9
1.2
|
L
 77.6%
H
0.6
1.2
|
L
 47.1%
H
0.6
1.2
|
L
 4.0%
H
0.6
1.2
|
L
 -77.1%
H
0.6
10
|
L
 -83.1%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Grifols SA (ADR) - Level III |
|
5,342.5
|
7.9
|
L
 -1.6%
H
7.8
8.1
|
L
 -1.6%
H
7.8
8.2
|
L
 -0.8%
H
7.5
8.5
|
L
 -13.7%
H
7.4
9.1
|
L
 -5.5%
H
7.4
11.1
|
L
 -8.8%
H
5.3
12.2
|
L
 -55.1%
H
5.3
19.1
|
L
 -51.2%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
7,892.5
|
66.5
|
L
 -2.4%
H
66.4
68.6
|
L
 -2.6%
H
66.4
70.0
|
L
 5.5%
H
62.4
73.9
|
L
 -4.3%
H
61.3
73.9
|
L
 18.7%
H
51.1
82.2
|
L
 102.6%
H
31.9
82.2
|
L
 60.7%
H
29.9
82.2
|
L
 565.4%
H
7.7
82.2
|
| HCW Biologics Inc |
|
14.2
|
2.0
|
L
 -5.3%
H
2.0
2.2
|
L
 -31.5%
H
1.9
3.0
|
L
 382.9%
H
0.3
4.0
|
L
 266.7%
H
0.3
4.0
|
L
 -74.4%
H
0.3
7.8
|
L
 -96.7%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
36.4
|
3.1
|
L
 -0.3%
H
3.0
3.2
|
L
 -11.9%
H
3.0
3.6
|
L
 -0.6%
H
2.9
3.9
|
L
 -38.9%
H
2.9
5.2
|
L
 113.8%
H
1.1
9.1
|
L
 -64.7%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
30.7
|
1.5
|
L
 -14.1%
H
1.2
1.7
|
L
 111.6%
H
0.7
2.2
|
L
 102.8%
H
0.5
2.2
|
L
 44.6%
H
0.5
2.2
|
L
 75.9%
H
0.5
2.2
|
L
 -9.9%
H
0.5
4.3
|
L
 -96.0%
H
0.5
55
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
21.9
|
0.5
|
L
 -2.2%
H
0.4
0.5
|
L
 2.3%
H
0.4
0.5
|
L
 -33.8%
H
0.4
0.8
|
L
 -25%
H
0.4
1.1
|
L
 -62.8%
H
0.4
2.4
|
L
 -86.4%
H
0.4
8.2
|
L
 -97.0%
H
0.4
21.7
|
L
H
0.4
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,828.8
|
31.6
|
L
 0.3%
H
31.2
31.8
|
L
 4.8%
H
30.1
31.8
|
L
 1.7%
H
28.9
33
|
L
 10.7%
H
26.3
35.0
|
L
 -8.4%
H
25.5
40.9
|
L
 -9.9%
H
18.6
41.6
|
L
 -1.2%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,312.5
|
35.2
|
L
 -0.5%
H
34.5
35.9
|
L
 6.7%
H
32.7
36
|
L
 -12.5%
H
28.5
41.7
|
L
 -35.0%
H
28.5
54.3
|
L
 25.3%
H
27.2
54.9
|
L
 83.8%
H
7.6
59.2
|
L
 282.7%
H
5.4
59.2
|
L
 778.1%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
164.7
|
0.9
|
L
 -2.3%
H
0.9
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -26.9%
H
0.8
1.3
|
L
 -26.9%
H
0.7
1.3
|
L
 -53.7%
H
0.7
2.3
|
L
 -26.9%
H
0.5
3.9
|
L
 -93.4%
H
0.5
16.6
|
L
 -95.5%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
43.9
|
6.9
|
L
 -2.3%
H
6.7
7.2
|
L
 -25.8%
H
6.4
10.8
|
L
 21.4%
H
4.6
10.8
|
L
 93.2%
H
2.1
10.8
|
L
 -49.0%
H
2.1
38.3
|
L
 -89.5%
H
2.1
109.2
|
L
 -94.0%
H
2.1
146.3
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
288.6
|
1.3
|
L
 1.6%
H
1.2
1.3
|
L
 23.8%
H
1.0
1.3
|
L
 58.5%
H
0.8
1.3
|
L
 16.1%
H
0.6
1.3
|
L
 -51.3%
H
0.6
2.9
|
L
 -63.2%
H
0.6
10.0
|
L
 -86.9%
H
0.6
17.5
|
L
H
0.6
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
1,968.8
|
11.5
|
L
 2.0%
H
11.1
11.5
|
L
 -4.5%
H
11.1
12.0
|
L
 -14.3%
H
11.1
13.6
|
L
 -20.1%
H
11.1
15.8
|
L
 -17.6%
H
11.1
19.5
|
L
 -5.1%
H
10.7
21.9
|
L
 -61.5%
H
7.4
43.9
|
L
 -12.6%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,876.1
|
7.5
|
L
 -2.6%
H
7.2
7.7
|
L
 4.2%
H
7.2
8.3
|
L
 8.1%
H
6.9
8.7
|
L
 -23.1%
H
6.5
11.0
|
L
 182.7%
H
2.0
12.4
|
L
 202.0%
H
1.3
12.4
|
L
 -57.2%
H
1.2
18.1
|
L
H
1.2
40.8
|
| Immucell Corp |
|
92.6
|
10.2
|
L
 3.4%
H
9.8
10.5
|
L
 1.2%
H
9.7
10.8
|
L
 21.3%
H
8.0
10.8
|
L
 55.9%
H
6
10.8
|
L
 60%
H
4.5
10.8
|
L
 102.4%
H
3.3
10.8
|
L
 4.8%
H
3.3
11.0
|
L
 51.0%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
2,589.3
|
29.5
|
L
 0.4%
H
29.1
29.8
|
L
 1.3%
H
28.6
30.0
|
L
 5.1%
H
27.7
30.0
|
L
 -8.5%
H
27.7
38.1
|
L
 48.2%
H
19.8
39.3
|
L
 34.8%
H
13.5
47.7
|
L
 46.3%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
353.5
|
2.4
|
L
 0.8%
H
2.3
2.4
|
L
 -8.1%
H
2.3
2.9
|
L
 21.2%
H
1.9
3.0
|
L
 160.9%
H
0.8
3.0
|
L
 200%
H
0.7
3.0
|
L
 -42.2%
H
0.7
4.7
|
L
 -21.3%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
66.3
|
5.9
|
L
 -0.7%
H
5.8
6
|
L
 5.8%
H
5.3
6.0
|
L
 -0.8%
H
5.1
6.2
|
L
 -12.5%
H
3.9
6.7
|
L
 -58.8%
H
3.9
18
|
L
 -91.6%
H
3.9
88.6
|
L
 -97.3%
H
3.9
220.4
|
L
H
3.9
451.3
|
| Inhibikase Therapeutics Inc |
|
231.1
|
1.8
|
L
 -1.1%
H
1.7
1.8
|
L
 3.6%
H
1.7
1.8
|
L
 -5.9%
H
1.5
2.1
|
L
 -14.6%
H
1.5
2.1
|
L
 -12.9%
H
1.3
2.3
|
L
 -53.7%
H
0.8
4.4
|
L
 -94.5%
H
0.8
38.5
|
L
H
0.8
70.8
|
| Illumina Inc |
|
24,655.8
|
163.0
|
L
 2.7%
H
158.1
165.4
|
L
 12.9%
H
142.6
165.4
|
L
 35.4%
H
121.4
165.4
|
L
 21.2%
H
115.3
165.4
|
L
 98.2%
H
78.8
165.4
|
L
 -16.2%
H
68.7
213.1
|
L
 -59.8%
H
68.7
526
|
L
 13.3%
H
68.7
555.8
|
| IM Cannabis Corp |
|
1.8
|
0.3
|
L
H
0.3
0.4
|
L
 20.8%
H
0.2
0.4
|
L
 11.5%
H
0.2
0.4
|
L
 -57.4%
H
0.2
1.1
|
L
 -95.3%
H
0.2
7.1
|
L
 -95.5%
H
0.2
8.6
|
L
 -99.9%
H
0.2
381
|
L
H
0.2
697.8
|
| Immix Biopharma Inc |
|
640.7
|
9
|
L
 1.8%
H
8.5
9.1
|
L
 2.5%
H
8.5
9.8
|
L
 4.3%
H
8
10.8
|
L
 11.5%
H
7.9
11.6
|
L
 284.6%
H
1.9
11.6
|
L
 336.9%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immunome Inc |
|
2,472.3
|
21.8
|
L
 -3.2%
H
21.8
22.8
|
L
 0.8%
H
20.9
22.8
|
L
 -4.9%
H
19.5
24.0
|
L
 -0.1%
H
19.2
24.9
|
L
 149.2%
H
8.0
27.7
|
L
 326.4%
H
4.5
31.0
|
L
 4.3%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
9.2
|
2.2
|
L
 -5.2%
H
2.2
2.5
|
L
 -0.9%
H
2.1
2.5
|
L
 -18.7%
H
2.1
3.0
|
L
 -32.9%
H
2.1
3.6
|
L
 -94.2%
H
2.1
47.4
|
L
 -88.6%
H
2.1
54.8
|
L
 -99.2%
H
2.1
348.8
|
L
 -100.0%
H
2.1
4599
|
| Immuneering Corp (Class A) |
|
373.3
|
5.8
|
L
 14.0%
H
5.1
5.8
|
L
 7.1%
H
5
6.0
|
L
 9.9%
H
4.8
6.9
|
L
 15.6%
H
4.7
6.9
|
L
 237.4%
H
1.7
10.1
|
L
 -16.7%
H
1
11.9
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,573.1
|
11.5
|
L
 0.5%
H
11.2
11.5
|
L
 -1.0%
H
10.9
11.7
|
L
 2.8%
H
10.2
11.9
|
L
 11.3%
H
9.1
11.9
|
L
 113.5%
H
5.1
12.4
|
L
 17.9%
H
3.3
13.8
|
L
 2.5%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
203.8
|
15.0
|
L
 -0.1%
H
14.8
15.8
|
L
 14.6%
H
12.1
15.8
|
L
 49.2%
H
9.1
15.8
|
L
 46.7%
H
8.5
15.8
|
L
 126.7%
H
5.1
15.8
|
L
 -14.0%
H
5.1
31.1
|
L
 -88.9%
H
5.1
151.2
|
L
 -99.5%
H
5.1
3900
|
| Immunovant Inc |
|
6,836.8
|
33.3
|
L
 -0.6%
H
32.6
33.7
|
L
 -2.5%
H
32.1
35.5
|
L
 23.6%
H
25.8
36.3
|
L
 20.1%
H
22.8
36.3
|
L
 124.2%
H
14.3
36.3
|
L
 59.9%
H
12.7
45.6
|
L
 119.7%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
18.4
|
1.9
|
L
 3.9%
H
1.8
1.9
|
L
 12.0%
H
1.7
1.9
|
L
 23.8%
H
1.4
1.9
|
L
 10%
H
1.3
2.1
|
L
 1146.7%
H
0.1
4.2
|
L
 -35.1%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,927.8
|
104.0
|
L
 0.0%
H
101.4
105.4
|
L
 2.7%
H
98.6
108.8
|
L
 -16.7%
H
98.6
151.0
|
L
 40.3%
H
57.3
155.3
|
L
 672.2%
H
12.7
155.3
|
L
 342.4%
H
10.8
155.3
|
L
 391.5%
H
7.7
155.3
|
L
H
7.7
155.3
|
| Incyte |
|
19,326.9
|
96.7
|
L
 -0.8%
H
96.2
98
|
L
 -0.4%
H
96.2
98.9
|
L
 -2.4%
H
94.1
103.0
|
L
 -4.5%
H
89.3
103.0
|
L
 48.7%
H
63.9
112.3
|
L
 56.4%
H
50.3
112.3
|
L
 15.5%
H
50.3
112.3
|
L
 14.4%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
199.3
|
1.8
|
L
 22.2%
H
1.4
1.8
|
L
 44.3%
H
1.1
1.8
|
L
 -39.7%
H
0.9
3.1
|
L
 -14.6%
H
0.9
3.8
|
L
 417.7%
H
0.3
13.4
|
L
 6.7%
H
0.3
13.4
|
L
 -88.3%
H
0.3
28.8
|
L
 -99.4%
H
0.3
8800
|
| Indivior PLC |
|
4,257.7
|
36.0
|
L
 -1.6%
H
35.5
36.6
|
L
 -4.0%
H
35.5
38.6
|
L
 5.5%
H
34.9
41
|
L
 10.1%
H
27.7
41
|
L
 180.1%
H
12.3
41
|
L
 98.7%
H
7.3
41
|
L
 1575.3%
H
2.0
41
|
L
 1329.4%
H
0.4
41
|
| MiNK Therapeutics Inc |
|
60.8
|
12.2
|
L
H
11.7
13
|
L
 12.2%
H
10.1
13
|
L
 3.3%
H
9.5
13
|
L
 11.4%
H
8.5
16.9
|
L
 73.5%
H
6.8
76
|
L
 -35.1%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
5.2
|
1.6
|
L
 -6.6%
H
1.6
1.7
|
L
 -8.7%
H
1.6
1.8
|
L
 124.3%
H
0.6
2.0
|
L
 84.7%
H
0.6
2.0
|
L
 -37.0%
H
0.6
8.0
|
L
 -93.8%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1755
|
L
 -99.9%
H
0.6
32175
|
| INmune Bio Inc |
|
37.5
|
1.4
|
L
 -0.7%
H
1.3
1.4
|
L
 -2.8%
H
1.3
1.5
|
L
 6.0%
H
1.3
1.8
|
L
 9.3%
H
1.1
1.8
|
L
 -80.9%
H
1.1
11.6
|
L
 -82.1%
H
1.1
14.7
|
L
 -89.6%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Inovio Pharma Inc |
|
107.8
|
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 -3.0%
H
1.2
1.4
|
L
 17.0%
H
1.1
1.8
|
L
 -27.6%
H
1.0
1.8
|
L
 -34.5%
H
1.0
3.0
|
L
 122.0%
H
0.3
14.8
|
L
 -82.6%
H
0.3
14.8
|
L
 -87.7%
H
0.3
33.8
|
| Insmed Inc |
|
23,173.0
|
106.9
|
L
 -1.4%
H
106.3
108.5
|
L
 0.6%
H
105
110.0
|
L
 -20.8%
H
98.9
142.9
|
L
 -28.4%
H
98.9
166.2
|
L
 53.3%
H
69.6
212.8
|
L
 472.0%
H
18.6
212.8
|
L
 334.6%
H
16.0
212.8
|
L
 803.7%
H
9.0
212.8
|
| Innoviva Inc |
|
1,581.0
|
21.4
|
L
 -2.2%
H
21.3
21.9
|
L
 -4.6%
H
21.3
23.0
|
L
 -7.1%
H
21.3
24.0
|
L
 -6.7%
H
21.3
24.5
|
L
 9.5%
H
16.5
25.1
|
L
 65.2%
H
12.2
25.1
|
L
 59.3%
H
10.6
25.1
|
L
 92.1%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
12,642.6
|
76.5
|
L
 -1.1%
H
76.4
78.1
|
L
 1.2%
H
74.7
78.1
|
L
 2.2%
H
71.9
79.2
|
L
 -5.7%
H
68.9
82.8
|
L
 128.3%
H
33.4
86.7
|
L
 88.7%
H
24.0
86.7
|
L
 105.4%
H
24.0
86.7
|
L
 247.7%
H
20.5
86.7
|
| Iovance Biotherapeutics Inc |
|
1,830.7
|
4.1
|
L
 -4.7%
H
3.9
4.2
|
L
 -0.2%
H
3.9
4.5
|
L
 23.9%
H
3.3
4.5
|
L
 6.2%
H
3.2
5.6
|
L
 134.3%
H
1.7
5.6
|
L
 -53.7%
H
1.6
18.3
|
L
 -77.9%
H
1.6
28
|
L
 -29.6%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
441.9
|
2.5
|
L
 2.9%
H
2.3
2.5
|
L
 8.4%
H
2.2
2.5
|
L
 11.4%
H
2.1
2.5
|
L
 5.6%
H
1.9
3.0
|
L
 362.3%
H
0.4
3.0
|
L
 -19.7%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,657.5
|
69.6
|
L
 -1.7%
H
68.8
71.9
|
L
 4.1%
H
66.2
71.9
|
L
 5.5%
H
63.8
72.8
|
L
 4.4%
H
57.7
72.8
|
L
 49.0%
H
40
99.5
|
L
 109.9%
H
25.6
99.5
|
L
 -43.4%
H
11.6
129.5
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
587.7
|
3.6
|
L
 -0.8%
H
3.5
3.7
|
L
 -8.9%
H
3.5
4.0
|
L
 -14.0%
H
3.4
4.9
|
L
 4.4%
H
3.0
4.9
|
L
 495%
H
0.6
5.8
|
L
 -66.8%
H
0.5
15.7
|
L
 -69.1%
H
0.5
15.7
|
L
 -65.5%
H
0.5
17.7
|
| Invivyd Inc |
|
335.9
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 3.6%
H
1.1
1.2
|
L
 -16.2%
H
1.0
1.6
|
L
 -32.5%
H
1.0
2.0
|
L
 21.3%
H
0.5
3.1
|
L
 -25.5%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
212.1
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 4.0%
H
1.8
1.9
|
L
 -21.7%
H
1.7
2.6
|
L
 -43.9%
H
1.7
3.9
|
L
 40.5%
H
1.2
6.8
|
L
 -42.1%
H
0.6
6.8
|
L
 -97.7%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,469.5
|
28.9
|
L
 -0.3%
H
28.5
29.2
|
L
 0.2%
H
28.2
30
|
L
 3.5%
H
27.6
31.5
|
L
 -10.6%
H
27.6
33.9
|
L
 -21.1%
H
27.6
40.7
|
L
 -46.7%
H
23.2
77.0
|
L
 -29.5%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
64.8
|
0.4
|
L
H
0.4
0.4
|
L
 -10.2%
H
0.4
0.5
|
L
 -8.3%
H
0.4
0.6
|
L
 -84.3%
H
0.3
2.8
|
L
 -76.6%
H
0.3
3.5
|
L
 -78.1%
H
0.3
3.5
|
L
 -91.3%
H
0.3
5.4
|
L
 -87.3%
H
0.3
8.0
|
| Immuron Ltd (ADR) |
|
11.8
|
1.5
|
L
 19.8%
H
1.1
1.6
|
L
 45%
H
1.0
1.6
|
L
 79.0%
H
0.8
1.6
|
L
 88.3%
H
0.7
1.6
|
L
 -18.1%
H
0.7
2.4
|
L
 -26.4%
H
0.7
6.0
|
L
 -70.1%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
171.8
|
1.8
|
L
 5.2%
H
1.8
1.9
|
L
H
1.7
1.9
|
L
 23.7%
H
1.3
2.6
|
L
 6.4%
H
1.2
2.6
|
L
 -16.4%
H
1.2
2.6
|
L
 -38.8%
H
1.2
3.6
|
L
 -53.2%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
1,030.1
|
4.9
|
L
 -5.7%
H
4.9
5.1
|
L
 -2.8%
H
4.9
5.5
|
L
 -0.2%
H
4.8
6.1
|
L
 -24.0%
H
4.8
6.8
|
L
 45.4%
H
2.9
8.0
|
L
 62.7%
H
1.5
8.0
|
L
 -63.9%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
2.3
|
3.6
|
L
 7.9%
H
3.1
3.7
|
L
 22.0%
H
2.9
3.7
|
L
 -55.0%
H
2.5
8
|
L
 -88.6%
H
2.5
34.8
|
L
 -97.7%
H
2.5
152.6
|
L
 -100.0%
H
2.5
37800
|
L
 -100.0%
H
2.5
26932500
|
L
 -100.0%
H
2.5
880621875
|
| Janux Therapeutics Inc |
|
889.8
|
14.6
|
L
 -1.0%
H
14.4
14.8
|
L
 0.5%
H
14.3
14.8
|
L
 3.4%
H
13.4
14.9
|
L
 7.2%
H
13.0
16.6
|
L
 -38.7%
H
12.1
35.3
|
L
 31.7%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
14,838.0
|
236.5
|
L
 0.5%
H
232.4
241.0
|
L
 -1.4%
H
232.4
242
|
L
 18.3%
H
201.0
243.3
|
L
 24.5%
H
176.7
243.3
|
L
 118.8%
H
105
243.3
|
L
 86.4%
H
95.5
243.3
|
L
 32.8%
H
95.5
243.3
|
L
 55.5%
H
86.9
243.3
|
| Jasper Therapeutics Inc |
|
23.2
|
0.8
|
L
 -6.7%
H
0.8
0.9
|
L
 -7.8%
H
0.8
1.0
|
L
 -6.7%
H
0.8
1.0
|
L
 -39.9%
H
0.6
1.5
|
L
 -84.9%
H
0.6
7.2
|
L
 -48.1%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharma Inc |
|
41.5
|
2.2
|
L
 -2.6%
H
2.2
2.4
|
L
 -8.2%
H
2.1
2.4
|
L
 -59.1%
H
2.1
5.9
|
L
 -88.3%
H
2.1
25.5
|
L
 -98.8%
H
2.1
1030
|
L
 -99.7%
H
2.1
1030
|
L
 -100.0%
H
2.1
16943.3
|
L
H
2.1
66943.3
|
| KalVista Pharma Inc |
|
1,430.6
|
26.9
|
L
 0.4%
H
26.8
26.9
|
L
 0.3%
H
26.8
26.9
|
L
 0.8%
H
26.6
26.9
|
L
 65.1%
H
15.1
26.9
|
L
 127.7%
H
9.8
26.9
|
L
 188.3%
H
7.2
26.9
|
L
 -0.5%
H
4.1
30.7
|
L
 81.1%
H
4.1
45
|
| Kamada Ltd |
|
450.5
|
7.8
|
L
 -0.6%
H
7.8
7.9
|
L
 -0.3%
H
7.8
8.1
|
L
 -3.7%
H
7.4
8.7
|
L
 -10.2%
H
7.4
9.2
|
L
 14.0%
H
6.5
9.4
|
L
 56.8%
H
4.1
9.4
|
L
 33.0%
H
3.7
9.4
|
L
 109.9%
H
3.6
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
3,722.3
|
48.4
|
L
 -4.8%
H
48.1
50.8
|
L
 -9.1%
H
48.1
53.6
|
L
 -8.7%
H
48.1
59.9
|
L
 8.7%
H
41.5
59.9
|
L
 76.8%
H
26.3
59.9
|
L
 253.9%
H
13.6
59.9
|
L
 255.0%
H
7.4
59.9
|
L
H
5.0
59.9
|
| Kodiak Sciences Inc |
|
2,297.3
|
36.7
|
L
 1.6%
H
36.2
37.8
|
L
 1.3%
H
34.4
37.8
|
L
 -15.9%
H
32.9
46.6
|
L
 37.0%
H
21
47.8
|
L
 979.7%
H
3.3
47.8
|
L
 542.9%
H
1.4
47.8
|
L
 -56.1%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
11.9
|
2.7
|
L
 -5.3%
H
2.7
2.8
|
L
 4.7%
H
2.5
2.9
|
L
 14.0%
H
2.3
2.9
|
L
 28.2%
H
1.8
2.9
|
L
 -10.1%
H
1.8
4.2
|
L
 25.8%
H
0.4
5.6
|
L
 -98.5%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
206.2
|
9.1
|
L
 -0.1%
H
8.9
9.5
|
L
 11.5%
H
8.2
10.0
|
L
 8.3%
H
6.9
10.2
|
L
 -3.3%
H
5
10.2
|
L
 116.7%
H
3.7
11.0
|
L
 -72.7%
H
0.6
37.1
|
L
 -93.5%
H
0.6
221.0
|
L
 -93.7%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
222.7
|
11.3
|
L
 -1.2%
H
11.1
11.6
|
L
 0.5%
H
10.8
11.6
|
L
 1.4%
H
9.8
12.2
|
L
 -20.7%
H
9.8
14.4
|
L
 -20.5%
H
9.8
22.6
|
L
 -76.9%
H
9.1
73
|
L
 -79.4%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
9,110.1
|
309.0
|
L
 -0.4%
H
307.1
315.6
|
L
 3.2%
H
299.0
315.6
|
L
 18.9%
H
252.0
319.5
|
L
 12.1%
H
242
319.5
|
L
 145.3%
H
124
319.5
|
L
 167.7%
H
94.0
319.5
|
L
 373.7%
H
38.9
319.5
|
L
H
8.0
319.5
|
| TuHURA Biosciences Inc |
|
143.9
|
2.3
|
L
 -3.8%
H
2.2
2.4
|
L
 -9.6%
H
2.2
2.5
|
L
 7.6%
H
2.1
2.8
|
L
 35.3%
H
1.3
3.4
|
L
 -26.1%
H
0.4
3.9
|
L
 -97.9%
H
0.2
196
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
24.1
|
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 4.4%
H
0.7
1.0
|
L
 -18.2%
H
0.5
1.0
|
L
 -25.8%
H
0.3
2.1
|
L
 84.6%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
905.5
|
10.2
|
L
 2.3%
H
9.9
10.3
|
L
 -9.3%
H
9.9
11.4
|
L
 16.6%
H
8.7
11.5
|
L
 16.8%
H
7.5
11.5
|
L
 79.3%
H
5.5
12.5
|
L
 -22.8%
H
5.4
24.2
|
L
 -54.2%
H
5.4
24.2
|
L
 231.2%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,697.4
|
81.4
|
L
 -0.1%
H
80.8
82.9
|
L
 3.2%
H
78.0
82.9
|
L
 -0.1%
H
76.9
89.5
|
L
 -10.9%
H
73.3
91
|
L
 174.7%
H
36.7
103
|
L
 179.4%
H
9.6
103
|
L
 69.3%
H
9.6
103
|
L
H
9.6
103
|
| Kazia Therapeutics Ltd (ADR) |
|
146.0
|
12.8
|
L
 0.9%
H
12.3
13.3
|
L
 -6.4%
H
11.7
13.7
|
L
 2.9%
H
11.7
15.2
|
L
 51.2%
H
6.8
15.2
|
L
 236.3%
H
3.5
17.4
|
L
 -78.3%
H
2.9
79
|
L
 -97.3%
H
2.9
614
|
L
 -96.9%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
14.9
|
0.6
|
L
 -3.2%
H
0.6
0.6
|
L
 -7.7%
H
0.6
0.7
|
L
 -13.0%
H
0.6
0.7
|
L
 -14.3%
H
0.6
1.1
|
L
 -41.2%
H
0.5
1.6
|
L
 -17.8%
H
0.5
6.9
|
L
 -90.1%
H
0.5
12.5
|
L
 -79.9%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
188.3
|
5.0
|
L
 1.0%
H
4.9
5.0
|
L
 1.8%
H
4.8
5.0
|
L
 1.6%
H
4.2
5.4
|
L
 -30.3%
H
3.6
7.3
|
L
 -25.9%
H
3.6
9.0
|
L
 -37.3%
H
3.6
11.5
|
L
 -58.1%
H
1.5
12.9
|
L
 -56.2%
H
1.5
15.6
|
| Lifevantage Corp |
|
99.3
|
7.9
|
L
 2.6%
H
7.2
8.5
|
L
 40.3%
H
5.8
8.9
|
L
 55.8%
H
4.6
8.9
|
L
 71.1%
H
3.9
8.9
|
L
 -39.7%
H
3.9
15
|
L
 71.1%
H
3.9
27.4
|
L
 -1.3%
H
3.0
27.4
|
L
 -41.8%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
4,648.7
|
232.0
|
L
 -1.2%
H
230.0
237.1
|
L
 1.2%
H
228.7
238.8
|
L
 3.2%
H
200.0
238.8
|
L
 17.0%
H
188.7
247.4
|
L
 127.0%
H
100.7
247.4
|
L
 233.6%
H
49.3
247.4
|
L
 205.4%
H
46.8
247.4
|
L
 192.7%
H
36.9
247.4
|
| Longeveron Inc (Class A) |
|
24.3
|
0.8
|
L
 -6.1%
H
0.8
0.8
|
L
 -6.1%
H
0.8
0.9
|
L
 -11.5%
H
0.7
0.9
|
L
 42.6%
H
0.5
1.2
|
L
 -37.9%
H
0.5
1.8
|
L
 -97.4%
H
0.5
43.0
|
L
 -98.8%
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
52.9
|
0.5
|
L
 10.2%
H
0.5
0.6
|
L
 10.2%
H
0.5
0.6
|
L
 -29.0%
H
0.4
1.1
|
L
 -43.8%
H
0.4
1.1
|
L
 -87.9%
H
0.4
7.3
|
L
 -76.3%
H
0.4
7.3
|
L
 -88.1%
H
0.4
13.1
|
L
 -98.8%
H
0.4
90.9
|
| Lixte biotech Holdings Inc |
|
77.4
|
6.3
|
L
 4.3%
H
5.9
6.3
|
L
 6.3%
H
5.5
6.5
|
L
 78.6%
H
3.3
6.5
|
L
 116.3%
H
2.4
6.5
|
L
 434.2%
H
0.6
6.5
|
L
 -8.1%
H
0.6
9.5
|
L
 -77.2%
H
0.6
49.5
|
L
 -34.9%
H
0.6
110.4
|
| Lipocine Inc |
|
18.5
|
2.3
|
L
 -0.4%
H
2.2
2.3
|
L
 -0.4%
H
2.2
2.4
|
L
 -1.8%
H
2.1
2.5
|
L
 -77.4%
H
1.8
9.9
|
L
 -33.4%
H
1.8
12.4
|
L
 -51.7%
H
1.8
12.4
|
L
 -89.2%
H
1.8
32.1
|
L
 -98.5%
H
1.8
163.0
|
| Leap Therapeutics Inc |
|
120.3
|
1.1
|
L
 0.9%
H
1.0
1.2
|
L
 -5.8%
H
1.0
1.4
|
L
 32.9%
H
0.8
1.4
|
L
 82.3%
H
0.5
1.4
|
L
 197.4%
H
0.2
3.7
|
L
 -86.0%
H
0.2
10.2
|
L
 -93.0%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
5,501.1
|
61.9
|
L
 -0.3%
H
60.7
62.3
|
L
 1.4%
H
59.2
63.5
|
L
 62.2%
H
37.5
63.5
|
L
 99.4%
H
29.8
63.5
|
L
 314.6%
H
11.9
63.5
|
L
 679.1%
H
5.7
63.5
|
L
 1955.1%
H
2.3
63.5
|
L
H
2.3
63.5
|
| Larimar Therapeutics Inc |
|
361.5
|
3.5
|
L
 -0.3%
H
3.4
3.5
|
L
 0.9%
H
3.4
3.7
|
L
 -19.8%
H
3.2
4.4
|
L
 -34.5%
H
3.2
6
|
L
 54.7%
H
2.1
6.4
|
L
 -3.3%
H
1.6
13.7
|
L
 -58.1%
H
1.5
15.3
|
L
 -95.8%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
29.6
|
3.3
|
L
 -1.5%
H
3.1
3.4
|
L
 3.5%
H
3.1
3.4
|
L
 0.9%
H
3.0
3.4
|
L
 -20.7%
H
2.8
5.1
|
L
 24.5%
H
1.8
5.1
|
L
 -15.8%
H
1.8
5.1
|
L
 -85.7%
H
1.8
25.2
|
L
 -96.0%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
45.8
|
3.6
|
L
 2.6%
H
3.3
3.6
|
L
 2.6%
H
3.2
3.7
|
L
 81.3%
H
2.0
3.7
|
L
 27.3%
H
1.1
3.7
|
L
 17.7%
H
1.1
5.7
|
L
 -34.4%
H
1.1
12.0
|
L
 -76.3%
H
1.1
16.5
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
968.3
|
2.2
|
L
 -1.4%
H
2.1
2.2
|
L
 0.9%
H
2.0
2.3
|
L
 40.7%
H
1.5
2.5
|
L
 48.3%
H
1.4
2.5
|
L
 246.0%
H
0.6
2.5
|
L
 -24.8%
H
0.3
3.7
|
L
 -50.3%
H
0.3
6.3
|
L
 -84.1%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
404.4
|
17.3
|
L
 3.0%
H
16.3
17.5
|
L
 -0.7%
H
16.0
17.7
|
L
 -15.9%
H
15.5
21.5
|
L
 -27.8%
H
15.5
27.8
|
L
 98.5%
H
7.7
45
|
L
 -68.6%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
5,044.7
|
27.2
|
L
 -3.9%
H
26.5
28.5
|
L
 -7.5%
H
26.5
30.2
|
L
 19.3%
H
22.4
30.4
|
L
 43.0%
H
16.7
30.4
|
L
 -6.2%
H
16.2
45.3
|
L
 -57.6%
H
16.2
77.3
|
L
 -31.0%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
5.1
|
0.7
|
L
 6.4%
H
0.6
0.7
|
L
 6.4%
H
0.6
0.7
|
L
 -10.7%
H
0.6
0.8
|
L
 -33.7%
H
0.6
1.0
|
L
 -48.9%
H
0.5
7
|
L
 -99.8%
H
0.1
408.5
|
L
 -100.0%
H
0.1
3045
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
136.3
|
2.0
|
L
 5.2%
H
1.9
2.2
|
L
 18.7%
H
1.7
2.2
|
L
 -0.5%
H
1.7
2.3
|
L
 -15.8%
H
1.7
2.9
|
L
 -20.1%
H
1.6
4.7
|
L
 1.0%
H
0.8
4.7
|
L
 -73.6%
H
0.8
9.6
|
L
 -99.5%
H
0.8
403.7
|
| Moleculin Biotech Inc |
|
14.9
|
2.8
|
L
 1.8%
H
2.7
2.9
|
L
 16.7%
H
2.4
2.9
|
L
 11.2%
H
2
2.9
|
L
 16.7%
H
1.8
2.9
|
L
 -87.2%
H
1.8
24
|
L
 -98.8%
H
1.8
3318.8
|
L
 -99.8%
H
1.8
3318.8
|
L
H
1.8
21555
|
| Seres Therapeutics Inc |
|
70.9
|
7.3
|
L
 -3.4%
H
7.3
7.8
|
L
 -7.6%
H
7.3
8.1
|
L
 3.8%
H
6.9
8.3
|
L
 -16.3%
H
6.6
9.6
|
L
 3.8%
H
6.6
30.0
|
L
 55.7%
H
0.4
30.0
|
L
 -65.3%
H
0.4
30.0
|
L
 -75.2%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
11,464.9
|
497.3
|
L
 -3.6%
H
496.6
520.3
|
L
 -3.9%
H
496.6
535.8
|
L
 -4.1%
H
490.1
559
|
L
 15.1%
H
416.2
572.2
|
L
 80.7%
H
268.7
615
|
L
 77.6%
H
119.8
615
|
L
 342.8%
H
52.3
615
|
L
 3831.0%
H
6.6
615
|
| MediWound Ltd |
|
184.2
|
14.3
|
L
 -1.6%
H
14.2
15
|
L
 -13.6%
H
14.1
16.9
|
L
 -11.8%
H
14.1
17.6
|
L
 -17.2%
H
14.1
18.1
|
L
 -34.7%
H
14.1
22.5
|
L
 59.4%
H
7.1
24
|
L
 -39.8%
H
7.1
43.5
|
L
 -73.6%
H
7.1
60.1
|
| MEI Pharma Inc |
|
34.4
|
1.0
|
L
 -1.0%
H
1.0
1.0
|
L
 -5.6%
H
1.0
1.1
|
L
 -12.2%
H
1.0
1.3
|
L
 -10.6%
H
1.0
1.3
|
L
 -54.9%
H
1.0
9
|
L
 -86.0%
H
1.0
9
|
L
 -98.2%
H
1.0
71
|
L
 -96.4%
H
1.0
102.8
|
| Macrogenics Inc |
|
264.4
|
4.2
|
L
 -1.2%
H
4.1
4.3
|
L
 -8.2%
H
4.1
4.6
|
L
 41.5%
H
2.9
4.6
|
L
 109.1%
H
1.8
4.6
|
L
 205.9%
H
1.2
4.6
|
L
 -10.9%
H
1.0
21.9
|
L
 -87.1%
H
1.0
32.8
|
L
 -83.0%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
7.4
|
0.4
|
L
 -10.4%
H
0.4
0.5
|
L
 -4.4%
H
0.4
0.6
|
L
 30.3%
H
0.3
0.6
|
L
 -20.4%
H
0.2
0.6
|
L
 -80.3%
H
0.2
2.8
|
L
 -60.6%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
93.0
|
L
 2.4%
H
90.0
93.6
|
L
 7.6%
H
85.4
93.6
|
L
 11.4%
H
80.3
93.6
|
L
 68.5%
H
52.1
96.5
|
L
 434.9%
H
16.6
96.5
|
L
 822.7%
H
9.9
96.5
|
L
 -52.9%
H
5.1
207.7
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
986.3
|
10.7
|
L
 6.5%
H
9.9
10.7
|
L
 15.3%
H
9.3
10.7
|
L
 19.0%
H
9.0
10.7
|
L
 40.9%
H
6.6
11.9
|
L
 108.0%
H
5.1
11.9
|
L
 56.2%
H
3.5
11.9
|
L
 -22.8%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
6,189.6
|
101.5
|
L
 1.9%
H
98.2
101.9
|
L
 2.9%
H
94.3
101.9
|
L
 7.8%
H
88.3
115.0
|
L
 10.0%
H
84.3
115.0
|
L
 128.3%
H
43.5
115.0
|
L
 289.8%
H
23.1
115.0
|
L
 513.7%
H
12.8
115.0
|
L
H
6.5
115.0
|
| Milestone Pharma Inc |
|
176.8
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 0.7%
H
1.4
1.5
|
L
 -22.0%
H
1.4
2.0
|
L
 -17.0%
H
1
2.3
|
L
 -12.4%
H
1
3.1
|
L
 -65.1%
H
0.6
4.1
|
L
 -76.5%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,411.9
|
19.2
|
L
 2.7%
H
18.6
19.6
|
L
 5.4%
H
17.9
19.6
|
L
 19.1%
H
15.8
21
|
L
 9.5%
H
15.8
21
|
L
 -50.8%
H
6.0
62.8
|
L
 -31.2%
H
6.0
65.0
|
L
 91.8%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,598.7
|
31.5
|
L
 -0.1%
H
31.0
32.1
|
L
 5.5%
H
29.4
32.1
|
L
 23.2%
H
25.6
32.1
|
L
 7.7%
H
22.4
32.1
|
L
 102.2%
H
12.6
47.7
|
L
 120.1%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,164.7
|
3.8
|
L
 3.6%
H
3.5
3.9
|
L
 11.5%
H
3.4
3.9
|
L
 37.1%
H
2.7
4.3
|
L
 14.9%
H
2.2
4.3
|
L
 -9.2%
H
2.2
6.5
|
L
 -14.9%
H
2.2
7.6
|
L
 -14.7%
H
2.2
7.6
|
L
 -22.4%
H
0.7
7.6
|
| Mind Medicine Inc |
|
2,638.3
|
24.2
|
L
 3.0%
H
23.3
24.3
|
L
 7.5%
H
22.4
24.3
|
L
 18.1%
H
19.3
24.3
|
L
 38.6%
H
16.6
26.3
|
L
 233.2%
H
6.3
26.3
|
L
 560.9%
H
2.4
26.3
|
L
 -52.6%
H
2.1
60.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
66.9
|
1.4
|
L
 -0.7%
H
1.3
1.4
|
L
 -2.9%
H
1.3
1.4
|
L
 -0.7%
H
1.3
1.5
|
L
 -6.2%
H
1.3
1.6
|
L
 -2.2%
H
1.2
2.0
|
L
 -36.4%
H
1.1
2.7
|
L
 -67.8%
H
1.1
5.1
|
L
 -79.8%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
435.7
|
65.0
|
L
 1.0%
H
63.3
66.6
|
L
 3.0%
H
60.7
68.8
|
L
 29.8%
H
50.3
68.8
|
L
 18.7%
H
50.1
68.8
|
L
 105.0%
H
29.2
105
|
L
 1104.4%
H
1.4
105
|
L
 127.8%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
26.2
|
1.6
|
L
 4.0%
H
1.5
1.6
|
L
 12.1%
H
1.4
1.6
|
L
 8.3%
H
1.4
1.6
|
L
 6.1%
H
1.2
1.8
|
L
 0.6%
H
0.8
4.1
|
L
 18.0%
H
0.8
9.7
|
L
 -94.6%
H
0.7
36.5
|
L
 -97.7%
H
0.7
135.5
|
| Moderna |
|
18,724.3
|
47.2
|
L
 -0.8%
H
46.8
49.3
|
L
 0.7%
H
45.9
49.3
|
L
 3.2%
H
43.7
59.5
|
L
 -11.9%
H
43.7
59.6
|
L
 77.7%
H
22.3
59.6
|
L
 -63.4%
H
22.3
170.5
|
L
 -74.5%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
708.0
|
4.8
|
L
 3.5%
H
4.7
5.0
|
L
 9.1%
H
4.3
5.0
|
L
 37.9%
H
3.5
5
|
L
 34.8%
H
2.8
5
|
L
 113.3%
H
2.0
5
|
L
 -60.9%
H
1.7
14.9
|
L
 -87.2%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
11.0
|
5.7
|
L
 -0.2%
H
5.4
5.8
|
L
 30.4%
H
4.2
5.8
|
L
 27.8%
H
3.8
6.5
|
L
 -16.4%
H
3.8
8.5
|
L
 -42.9%
H
3.8
12.5
|
L
 -54.4%
H
3.8
16.5
|
L
 -77.3%
H
3.8
49.1
|
L
 -72.5%
H
3.8
49.1
|
| MaxCyte Inc |
|
129.6
|
1.2
|
L
 3.4%
H
1.1
1.3
|
L
 16.4%
H
1.0
1.3
|
L
 47.6%
H
0.8
1.3
|
L
 49.4%
H
0.7
1.3
|
L
 -49.2%
H
0.6
2.4
|
L
 -69.8%
H
0.6
5.5
|
L
 -79.3%
H
0.6
17.4
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
34.3
|
4.4
|
L
 -8.2%
H
4.2
4.8
|
L
 4.6%
H
3.9
4.8
|
L
 21.1%
H
3.6
5.5
|
L
 17.2%
H
3.1
5.5
|
L
 -72.7%
H
2.5
33.6
|
L
 -99.9%
H
2.5
6387
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
58.3
|
2.6
|
L
 -14.1%
H
2.4
2.8
|
L
 -23.1%
H
2.4
4.0
|
L
 456.5%
H
0.3
4.9
|
L
 236.8%
H
0.3
4.9
|
L
 27.4%
H
0.3
4.9
|
L
 -98.8%
H
0.3
240
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
1,991.0
|
15.4
|
L
 4.3%
H
15.1
15.6
|
L
 1.3%
H
14.5
15.6
|
L
 -1.0%
H
14.3
16.1
|
L
 -2.8%
H
13.3
16.9
|
L
 44.7%
H
9.9
21.5
|
L
 342.5%
H
1.0
22
|
L
 99.2%
H
1.0
22
|
L
 125.5%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
157.5
|
4.2
|
L
 5%
H
4.1
4.2
|
L
 0.5%
H
4
4.2
|
L
 -5.6%
H
3.7
4.5
|
L
 -16.3%
H
3.7
5.3
|
L
 10.2%
H
3.4
5.4
|
L
 -35.4%
H
3.3
12.7
|
L
 -83.4%
H
3.3
32.0
|
L
 -84.4%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
54.3
|
0.3
|
L
H
0.3
0.4
|
L
 21.4%
H
0.3
0.4
|
L
 21.4%
H
0.2
0.4
|
L
 -8.1%
H
0.2
0.4
|
L
 -84.2%
H
0.2
3.1
|
L
 -64.9%
H
0.2
5.0
|
L
 -89.6%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
15.9
|
2.5
|
L
 -3.8%
H
2.5
2.7
|
L
 -0.4%
H
2.5
2.8
|
L
 -4.9%
H
2.4
2.8
|
L
 -6.3%
H
2.4
3.3
|
L
 -23.5%
H
2.3
5.0
|
L
 -66.8%
H
2.3
7.8
|
L
 -81.6%
H
2.3
19.9
|
L
 -79.6%
H
2.3
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,937.3
|
33.7
|
L
 -4.9%
H
33.3
36.2
|
L
 -5.0%
H
33.3
37.3
|
L
 18.5%
H
28.0
42.2
|
L
 -5.0%
H
27.9
42.2
|
L
 86.0%
H
17.6
42.2
|
L
 143.2%
H
5.6
42.2
|
L
 247.2%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Nature`s Sunshine Products Inc |
|
374.2
|
21.3
|
L
 -2.6%
H
21.2
21.9
|
L
 -2.6%
H
21.2
22.5
|
L
 -21.3%
H
21.1
27.4
|
L
 -23.1%
H
21.1
28.1
|
L
 37.7%
H
13.0
28.1
|
L
 91.0%
H
10.8
28.1
|
L
 3.9%
H
7.9
28.1
|
L
 129.6%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
348.2
|
2.7
|
L
 5.4%
H
2.5
2.8
|
L
 7.9%
H
2.4
2.8
|
L
 9.6%
H
2.3
3.2
|
L
 13.2%
H
2.2
4.3
|
L
 265.3%
H
0.6
4.3
|
L
 -8.4%
H
0.6
4.7
|
L
 -73.6%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
15,917.1
|
158.3
|
L
 1.2%
H
155.4
159.1
|
L
 1.0%
H
154.3
159.1
|
L
 20.6%
H
129.8
162.4
|
L
 19.7%
H
125.1
162.4
|
L
 28.7%
H
121.8
162.4
|
L
 75.7%
H
84.2
162.4
|
L
 64.5%
H
71.9
162.4
|
L
 242.7%
H
37.3
162.4
|
| Minerva Neurosciences Inc |
|
228.8
|
4.9
|
L
 -1.8%
H
4.9
5.0
|
L
 -6.7%
H
4.9
5.5
|
L
 -23.2%
H
4.3
6.6
|
L
 -25.6%
H
4.3
8.8
|
L
 218.8%
H
1.6
12.5
|
L
 -17.1%
H
1.2
13.5
|
L
 -79.2%
H
1.2
25.1
|
L
 -94.6%
H
1.2
126.7
|
| Nektar Therapeutics |
|
2,192.0
|
64.9
|
L
 -0.2%
H
63.3
65.5
|
L
 -2.6%
H
62.8
67.5
|
L
 -22.0%
H
62.8
88.1
|
L
 -5.9%
H
62.5
109
|
L
 496.3%
H
8.0
109
|
L
 597.6%
H
6.2
109
|
L
 -76.1%
H
6.2
290.6
|
L
 -71.5%
H
6.2
1670.4
|
| Nkarta Inc |
|
232.5
|
3.3
|
L
 -1.5%
H
3.2
3.3
|
L
 7.3%
H
3.0
3.3
|
L
 20.8%
H
2.6
3.4
|
L
 20.4%
H
2.0
3.7
|
L
 86.8%
H
1.6
3.7
|
L
 -29.8%
H
1.3
16.2
|
L
 -86.7%
H
1.3
40.6
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
19.0
|
3.5
|
L
 -0.6%
H
3.4
3.6
|
L
 11.4%
H
3
3.7
|
L
 2.9%
H
3.0
4.8
|
L
 21.4%
H
1.8
5.1
|
L
 -84%
H
1.8
30.8
|
L
 -99.2%
H
1.2
612
|
L
 -99.7%
H
1.2
1492
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
28.3
|
L
 3.1%
H
27.0
28.5
|
L
 2.3%
H
26.1
28.5
|
L
 7.0%
H
24.9
34.0
|
L
 20.7%
H
18.2
34.0
|
L
 66.6%
H
14.7
37.3
|
L
 73.9%
H
12.2
37.3
|
L
 -85.9%
H
7.5
222
|
L
 -81.5%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
9.2
|
L
 0.1%
H
9.1
9.2
|
L
 3.4%
H
8.9
9.3
|
L
 18.7%
H
8.0
9.3
|
L
 11.7%
H
7.0
9.3
|
L
 40.9%
H
6.2
9.3
|
L
 1293.9%
H
0.0
9.3
|
L
 -64.1%
H
0.0
31
|
L
H
0.0
1010
|
| MetaVia Inc |
|
14.7
|
2.8
|
L
 -8.4%
H
2.8
3.3
|
L
 -26.2%
H
2.7
3.8
|
L
 90.6%
H
1.0
4.3
|
L
 88.1%
H
1.0
4.3
|
L
 -60.3%
H
1.0
19.0
|
L
 -94.4%
H
1.0
74.3
|
L
 -100.0%
H
1.0
17344.8
|
L
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
1,836.5
|
17.8
|
L
 0.5%
H
17.6
18
|
L
 1.5%
H
17.1
18.1
|
L
 6.9%
H
15.1
18.1
|
L
 11.2%
H
14.0
18.1
|
L
 67.1%
H
8.2
22.5
|
L
 81.2%
H
4.2
29.6
|
L
 -36.3%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
29.6
|
0.8
|
L
 -4.7%
H
0.8
0.9
|
L
H
0.8
0.9
|
L
 2.5%
H
0.7
1.0
|
L
 -9.9%
H
0.6
1.1
|
L
 -46.8%
H
0.6
2.6
|
L
 -46.4%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
160.1
|
4.4
|
L
 -0.5%
H
4.3
4.6
|
L
 37.3%
H
3.3
4.6
|
L
 51.9%
H
2.7
4.6
|
L
 137.6%
H
1.6
4.6
|
L
 67.4%
H
1.6
4.6
|
L
 -36.9%
H
1.1
54
|
L
 -98.0%
H
1.1
262.4
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,965.9
|
14.1
|
L
 2.9%
H
13.1
14.3
|
L
 11.7%
H
12.2
14.3
|
L
 13.1%
H
11.8
15.6
|
L
 2.1%
H
11.6
17.0
|
L
 104.8%
H
6.9
28.3
|
L
 -62.5%
H
5.9
47.5
|
L
 -81.2%
H
5.9
202.7
|
L
 -52.3%
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
8,720.6
|
110.4
|
L
 1.0%
H
108.3
112.1
|
L
 8.1%
H
101.9
112.1
|
L
 11.4%
H
97.8
112.1
|
L
 8.3%
H
93.9
112.1
|
L
 48.0%
H
71.1
113.0
|
L
 170.6%
H
38.8
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,803.9
|
11.0
|
L
 6.3%
H
10.2
11.2
|
L
 19.1%
H
9.4
11.6
|
L
 37.6%
H
7.8
11.6
|
L
 8.2%
H
7.6
11.6
|
L
 49.5%
H
6.1
12.0
|
L
 47.6%
H
3.5
23.9
|
L
 -92.6%
H
3.5
277.8
|
L
 -90.6%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
258.6
|
9.8
|
L
 -4.3%
H
9.6
10.2
|
L
 -5.8%
H
9.6
10.7
|
L
 14.7%
H
8.4
13.3
|
L
 10.1%
H
7.2
13.3
|
L
 3.6%
H
5.6
13.3
|
L
 -43.3%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
22.4
|
6.2
|
L
 -3.1%
H
6.0
6.5
|
L
 -20.8%
H
5.8
7.9
|
L
 -30.7%
H
5.8
11.1
|
L
 -51.3%
H
5.8
14.4
|
L
 5.1%
H
4.6
15.7
|
L
 -70.5%
H
2.8
30.8
|
L
 -93.4%
H
2.8
110.2
|
L
H
2.8
1308
|
| NuCana PLC (ADR) |
|
9.7
|
2.3
|
L
 2.6%
H
2.2
2.4
|
L
 15.4%
H
2.0
2.4
|
L
 14.2%
H
1.8
2.4
|
L
 7.9%
H
1.3
2.4
|
L
 -99.8%
H
1.3
8000
|
L
 -100.0%
H
1.3
950000
|
L
 -100.0%
H
1.3
3319720
|
L
H
1.3
32000000
|
| Ocugen Inc |
|
467.2
|
1.4
|
L
 -2.1%
H
1.4
1.4
|
L
 3.0%
H
1.3
1.4
|
L
 -17.9%
H
1.3
1.9
|
L
 -24.2%
H
1.3
2.7
|
L
 64.3%
H
0.8
2.7
|
L
 200%
H
0.3
2.7
|
L
 -84.2%
H
0.3
17.7
|
L
 -98.9%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,370.8
|
22.7
|
L
 -23.4%
H
20.0
29.6
|
L
 -23.0%
H
20.0
30.7
|
L
 -14.2%
H
20.0
34.5
|
L
 -22.8%
H
20.0
34.5
|
L
 16.7%
H
16
34.5
|
L
 105.1%
H
9.1
34.5
|
L
 134.0%
H
6.3
34.5
|
L
H
6.3
34.5
|
| Ocular Therapeutix Inc |
|
1,972.8
|
9.0
|
L
 -1.5%
H
9.0
9.3
|
L
 9.5%
H
8.1
9.3
|
L
 -2.2%
H
7.9
10.0
|
L
 0.8%
H
7.4
11.5
|
L
 12.5%
H
6.2
16.4
|
L
 41.0%
H
2
16.4
|
L
 -38.1%
H
2
16.4
|
L
 -24.5%
H
2
24.3
|
| Opus Genetics Inc |
|
354.9
|
4.4
|
L
 3.8%
H
4.1
4.6
|
L
 2.4%
H
3.9
4.6
|
L
 -6.6%
H
3.9
5.4
|
L
 4.8%
H
3.8
5.8
|
L
 336%
H
0.9
5.8
|
L
 14.1%
H
0.7
5.8
|
L
 -4.0%
H
0.7
7
|
L
 -97.0%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
200.5
|
6.2
|
L
 -4.9%
H
6.0
6.5
|
L
 2.0%
H
6
6.8
|
L
 62.1%
H
3.7
6.9
|
L
 3.3%
H
2.4
6.9
|
L
 87.1%
H
2.3
8.5
|
L
 39.9%
H
1.9
8.5
|
L
 -93.0%
H
1.9
125
|
L
 -92.5%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
90.3
|
1.7
|
L
 0.6%
H
1.7
1.8
|
L
 5.5%
H
1.6
1.8
|
L
 13.2%
H
1.5
1.8
|
L
 0.6%
H
1.4
1.8
|
L
 -7.0%
H
1.4
3.4
|
L
 10.3%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
1,152.1
|
13.2
|
L
 3.4%
H
12.6
13.2
|
L
 -3.6%
H
12.4
14.0
|
L
 -6.7%
H
12.4
15.6
|
L
 -45.5%
H
12.4
24.7
|
L
 149.8%
H
3.9
36.3
|
L
 145.6%
H
2.9
36.3
|
L
 -52.8%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
799.0
|
11.0
|
L
 -1.0%
H
10.8
11.1
|
L
 -3.7%
H
10.6
12.0
|
L
 -24.2%
H
10.6
15.3
|
L
 -8.4%
H
9.8
15.3
|
L
 257.3%
H
3.0
17.7
|
L
 88.7%
H
0.9
17.7
|
L
 -27.3%
H
0.9
17.7
|
L
 -3.3%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
124.1
|
1.0
|
L
 10.6%
H
0.9
1.1
|
L
 28.4%
H
0.8
1.1
|
L
 19.5%
H
0.8
1.1
|
L
 -8.0%
H
0.8
1.2
|
L
 205.9%
H
0.3
1.5
|
L
 -39.5%
H
0.3
3.4
|
L
 -65.9%
H
0.3
3.4
|
L
 -74.3%
H
0.3
8.5
|
| Traws Pharma Inc |
|
22.1
|
1.5
|
L
 -4.0%
H
1.5
1.5
|
L
 -2.0%
H
1.5
1.7
|
L
 12.3%
H
1.3
3.2
|
L
 -11.5%
H
1
3.2
|
L
 2.8%
H
1
3.3
|
L
 -94.9%
H
1.0
31.5
|
L
 -99.1%
H
1.0
200
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
3.8
|
1.3
|
L
H
1.3
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 -9.0%
H
1.2
1.6
|
L
 -39.6%
H
1.2
2.2
|
L
 -27.2%
H
1.2
5.3
|
L
 -93.7%
H
0.3
24.6
|
L
 -98.8%
H
0.3
118.7
|
L
 -99.8%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
874.7
|
8.5
|
L
H
8.3
8.8
|
L
 1.6%
H
8.3
8.9
|
L
 -10.5%
H
7.7
10.1
|
L
 -37.2%
H
7.2
14.0
|
L
 3.4%
H
7.2
14.9
|
L
 67.7%
H
3.9
16.7
|
L
 -63.0%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
162.5
|
4.0
|
L
 0.3%
H
3.9
4.0
|
L
 -0.5%
H
3.8
4.1
|
L
 3.4%
H
3.8
5.0
|
L
 16.1%
H
3.2
5.0
|
L
 69.7%
H
2.0
5.0
|
L
 -1.2%
H
1.7
5.0
|
L
 -65.5%
H
1.7
31.5
|
L
 -55.4%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
108.5
|
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 135.5%
H
0.4
0.8
|
L
 180.8%
H
0.2
0.8
|
L
 73.8%
H
0.2
0.8
|
L
 -60.3%
H
0.2
3.0
|
L
 -99.9%
H
0.2
812
|
L
 -99.9%
H
0.2
1308
|
L
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
509.5
|
2.7
|
L
 3.4%
H
2.5
2.8
|
L
 10.5%
H
2.4
2.8
|
L
 1.5%
H
2.3
3.0
|
L
 67.5%
H
1.6
3.1
|
L
 911.1%
H
0.3
3.1
|
L
 -21.6%
H
0.2
4.1
|
L
 -34.2%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,249.0
|
30.8
|
L
 -3.3%
H
30.7
31.9
|
L
 -7.4%
H
30.7
35.0
|
L
 -41.4%
H
30.7
58.7
|
L
 -43.6%
H
30.7
60.1
|
L
 26.1%
H
22.9
60.1
|
L
 132.4%
H
9.4
60.1
|
L
 9.2%
H
9.4
60.1
|
L
 59.1%
H
9.4
60.1
|
| Palisade Bio Inc |
|
368.4
|
2.1
|
L
 2.9%
H
2.1
2.1
|
L
 8.7%
H
1.9
2.2
|
L
 9.8%
H
1.8
2.2
|
L
 19.8%
H
1.5
2.9
|
L
 186.5%
H
0.5
2.9
|
L
 -89.4%
H
0.4
36.6
|
L
 -99.9%
H
0.4
3427.5
|
L
 -100.0%
H
0.4
594000
|
| Passage Bio Inc |
|
18.5
|
5.8
|
L
 1.1%
H
5.7
5.9
|
L
 10.5%
H
5.0
5.9
|
L
 7.9%
H
3.9
5.9
|
L
 -36.7%
H
3.9
12.1
|
L
 -33.8%
H
3.9
20
|
L
 -70.2%
H
3.9
35.8
|
L
 -97.8%
H
3.9
322.8
|
L
H
3.9
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
1.2
|
1.2
|
L
 10.5%
H
1.0
1.2
|
L
 11.5%
H
1.0
1.3
|
L
 4.5%
H
1.0
1.3
|
L
 -92.5%
H
1.0
28.4
|
L
 -99.9%
H
1.0
1488
|
L
 -100.0%
H
1.0
5808
|
L
 -100.0%
H
1.0
43920
|
L
H
1.0
146400
|
| Puma biotech Inc |
|
364.9
|
7.2
|
L
 -1.0%
H
7.1
7.2
|
L
 1.3%
H
7.1
7.5
|
L
 -4.1%
H
6.6
7.9
|
L
 25.8%
H
5.5
7.9
|
L
 118.6%
H
3.0
7.9
|
L
 119.3%
H
2.1
7.9
|
L
 -32.0%
H
1.6
12.0
|
L
 -80.8%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
913.7
|
23.2
|
L
 -1.9%
H
23.2
24.2
|
L
 -0.6%
H
22.9
25.2
|
L
 -7.6%
H
21.9
27.1
|
L
 6.0%
H
21.0
27.1
|
L
 -10.1%
H
18.8
27.6
|
L
 -40.9%
H
11.2
41.7
|
L
 -61.7%
H
11.2
82.2
|
L
 -49.0%
H
11.2
82.2
|
| Processa Pharma Inc |
|
7.0
|
2.6
|
L
 -3.0%
H
2.5
2.6
|
L
 -3.4%
H
2.4
2.7
|
L
 -3.4%
H
2.4
3.4
|
L
 18.0%
H
2.1
3.5
|
L
 -65.0%
H
1.8
19.6
|
L
 -99.1%
H
1.8
450
|
L
 -99.9%
H
1.8
4495.5
|
L
 -100.0%
H
1.8
17937.5
|
| Vaxcyte Inc |
|
7,422.0
|
51.4
|
L
 0.7%
H
50.4
51.5
|
L
 8.7%
H
47.1
51.5
|
L
 -10.3%
H
46.4
59.7
|
L
 -16.8%
H
46.4
63.3
|
L
 58.2%
H
29.1
65
|
L
 5.4%
H
27.7
121.1
|
L
 143.9%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
60.3
|
1.1
|
L
 0.9%
H
1.0
1.1
|
L
 -10%
H
1.0
1.3
|
L
 12.5%
H
1.0
1.6
|
L
 58.8%
H
0.5
1.6
|
L
 -21.7%
H
0.5
1.9
|
L
 -87.2%
H
0.5
10.3
|
L
 -91.1%
H
0.5
17.9
|
L
 -99.3%
H
0.5
355.4
|
| PepGen Inc |
|
103.8
|
1.5
|
L
H
1.5
1.5
|
L
 -0.7%
H
1.5
1.6
|
L
 -3.2%
H
1.4
1.9
|
L
 -75.9%
H
1.3
6.8
|
L
 2.7%
H
1.0
7.8
|
L
 -90.5%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,547.3
|
4.3
|
L
 -3.8%
H
4.3
4.6
|
L
 2.4%
H
4.1
4.7
|
L
 5.3%
H
4.0
4.9
|
L
 14.5%
H
3.0
4.9
|
L
 228.8%
H
1.3
5.5
|
L
 252.8%
H
0.7
5.5
|
L
 -34.2%
H
0.7
8.7
|
L
 -85.5%
H
0.7
32.9
|
| Phathom Pharma Inc |
|
764.9
|
9.6
|
L
 -7.1%
H
9.5
10.5
|
L
 -15.4%
H
9.5
11.5
|
L
 -18.6%
H
9.5
13.4
|
L
 -23.7%
H
9.5
13.7
|
L
 125.7%
H
4.3
18.3
|
L
 -15.9%
H
2.2
19.7
|
L
 -72.9%
H
2.2
37.2
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
12.9
|
1.1
|
L
 -2.6%
H
1.1
1.1
|
L
 1.8%
H
1.1
1.1
|
L
 -5.9%
H
1.0
1.2
|
L
 -2.6%
H
1.0
1.4
|
L
 -44.5%
H
0.8
4.2
|
L
 -96.9%
H
0.6
32.3
|
L
 -99.5%
H
0.6
266.8
|
L
 -100.0%
H
0.6
194238
|
| Pharvaris NV |
|
2,107.6
|
30.2
|
L
 1%
H
29.6
30.4
|
L
 1.6%
H
29.1
30.6
|
L
 1.1%
H
28.3
33.3
|
L
 6.2%
H
25.0
33.3
|
L
 81.7%
H
15.9
33.3
|
L
 235.1%
H
8.2
33.3
|
L
 47.1%
H
1.8
33.3
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
78.0
|
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 4.1%
H
1.2
1.3
|
L
 4.1%
H
1.1
1.3
|
L
 -3.1%
H
1.1
1.4
|
L
 -6.7%
H
1.1
2.0
|
L
 -94.1%
H
1.1
24.7
|
L
 -95.8%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
25.0
|
2.3
|
L
 -1.3%
H
2.3
2.6
|
L
 -2.1%
H
2.3
2.6
|
L
 -32.2%
H
2.2
3.9
|
L
 -35.6%
H
2.2
3.9
|
L
 -48.0%
H
2.2
6.0
|
L
 -65.9%
H
0.7
8.6
|
L
 -92.1%
H
0.7
36.4
|
L
 -98.2%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
8.9
|
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 2.5%
H
0.8
0.9
|
L
 10.7%
H
0.7
1.0
|
L
 20.3%
H
0.6
1.0
|
L
 -18.6%
H
0.6
1.5
|
L
 -73.5%
H
0.6
3.2
|
L
 -95.6%
H
0.6
21.5
|
L
 -99.2%
H
0.6
253.4
|
| Praxis Precision Medicines Inc |
|
9,756.7
|
350.0
|
L
 -0.8%
H
338.1
355
|
L
 1.9%
H
338.1
366.5
|
L
 8.3%
H
306.8
366.5
|
L
 3.9%
H
271.9
366.5
|
L
 807.8%
H
37.2
366.5
|
L
 2587.9%
H
12.5
366.5
|
L
 19.1%
H
11.9
366.5
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
2.6
|
3
|
L
 119.0%
H
2.4
5.4
|
L
 101.3%
H
1.3
5.4
|
L
 59.6%
H
1.3
5.4
|
L
 1.0%
H
1.3
5.4
|
L
 55.4%
H
0.6
5.4
|
L
 -90.0%
H
0.2
158.5
|
L
 -98.3%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
312.2
|
3.9
|
L
 -0.3%
H
3.8
4
|
L
 -8.2%
H
3.8
4.4
|
L
 -8.2%
H
3.8
5.3
|
L
 42.0%
H
2.5
5.5
|
L
 340.5%
H
0.8
5.5
|
L
 -32.3%
H
0.6
6.8
|
L
 -88.7%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
641.2
|
3.6
|
L
 4.4%
H
3.3
3.6
|
L
 19.5%
H
2.9
3.6
|
L
 0.6%
H
2.7
3.7
|
L
 -23.2%
H
2.7
4.8
|
L
 200.9%
H
1.2
6.9
|
L
 -74.3%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
375.5
|
1.8
|
L
 1.1%
H
1.7
1.9
|
L
 4.6%
H
1.7
1.9
|
L
 0.6%
H
1.5
2.0
|
L
 -18.3%
H
1.5
2.6
|
L
 154.2%
H
0.5
7.1
|
L
 -83.7%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
166.5
|
1.6
|
L
 0.6%
H
1.5
1.6
|
L
 1.3%
H
1.5
1.6
|
L
 2.6%
H
1.4
1.7
|
L
 -0.6%
H
1.4
2.2
|
L
 -4.8%
H
1.3
3.1
|
L
 -10.7%
H
1.1
4.6
|
L
 -74.7%
H
0.5
9.1
|
L
 -67.4%
H
0.5
24
|
| Prothena Corporation plc |
|
533.0
|
10.2
|
L
 2%
H
9.8
10.2
|
L
 3.6%
H
9.5
10.3
|
L
 -6.4%
H
9.0
11.8
|
L
 17.4%
H
8.4
11.8
|
L
 121.8%
H
4.5
11.8
|
L
 -84.2%
H
4.3
77.1
|
L
 -65.1%
H
4.3
79.8
|
L
 -78.1%
H
4.3
79.8
|
| Alpha Compute Corp |
|
8.9
|
0.4
|
L
 -13.6%
H
0.4
0.4
|
L
 5.6%
H
0.4
0.6
|
L
 72.7%
H
0.2
0.6
|
L
 -7.3%
H
0.2
0.6
|
L
 -95.3%
H
0.2
13.8
|
L
 -99.4%
H
0.2
88
|
L
 -99.9%
H
0.2
899.5
|
L
 -99.8%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
40.1
|
5.8
|
L
 -9.5%
H
5.8
6.4
|
L
 -11.7%
H
5.8
7.1
|
L
 3.9%
H
5.1
7.3
|
L
 -23.2%
H
2.9
8.2
|
L
 -18.9%
H
2.9
23.4
|
L
 -94.0%
H
2.9
104
|
L
 -99.3%
H
2.9
1106.3
|
L
 -100.0%
H
2.9
555000
|
| PTC Therapeutics Inc |
|
6,125.8
|
73.9
|
L
 3.9%
H
71.6
74.0
|
L
 7.3%
H
67.2
74.0
|
L
 14.4%
H
63.2
79.9
|
L
 8.3%
H
61.4
79.9
|
L
 52.2%
H
43.2
87.5
|
L
 79.4%
H
17.5
87.5
|
L
 88.1%
H
17.5
87.5
|
L
 842.0%
H
4.0
87.5
|
| Protagonist Therapeutics Inc |
|
6,402.8
|
99.6
|
L
 -0.9%
H
98.8
102.4
|
L
 0.4%
H
97.9
103.7
|
L
 1.1%
H
96.7
105.7
|
L
 8.1%
H
87.8
107.8
|
L
 109.7%
H
47.5
107.8
|
L
 290.9%
H
13.7
107.8
|
L
 183.6%
H
6.9
107.8
|
L
H
4.5
107.8
|
| Pulmatrix Inc |
|
5.1
|
1.4
|
L
 0.7%
H
1.3
1.4
|
L
 3.7%
H
1.3
1.5
|
L
 12.1%
H
1.2
1.5
|
L
 -53.5%
H
1.2
2.5
|
L
 -84.5%
H
1.2
9.2
|
L
 -47.7%
H
1.2
10.4
|
L
 -92.5%
H
1.2
23.4
|
L
 -99.7%
H
1.2
1396
|
| Polypid Ltd |
|
90.5
|
4.7
|
L
 -0.8%
H
4.6
4.8
|
L
 -6.0%
H
4.6
5.2
|
L
 4.2%
H
4.2
5.2
|
L
 11.1%
H
4.0
5.2
|
L
 68.6%
H
2.8
5.2
|
L
 -57.5%
H
2.3
13.2
|
L
 -98.3%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
114.0
|
1.8
|
L
 1.1%
H
1.7
1.9
|
L
 -8.2%
H
1.6
2.0
|
L
 8.4%
H
1.6
2.9
|
L
 22.5%
H
1.3
2.9
|
L
 48.8%
H
1.0
5.6
|
L
 -44.8%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
917.4
|
13.0
|
L
 -4.9%
H
13.0
13.4
|
L
 3.1%
H
13.0
13.8
|
L
 -20.6%
H
11.8
17.0
|
L
 -20.3%
H
11.8
18.4
|
L
 22.6%
H
9.5
21.3
|
L
 8.2%
H
6.7
21.3
|
L
 6.9%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
2.8
|
3.0
|
L
 6.4%
H
2.8
3.1
|
L
 3.8%
H
2.7
3.1
|
L
 -29.3%
H
2.5
4.5
|
L
 -32.4%
H
2.5
5.2
|
L
 -88.5%
H
2.5
29
|
L
 -100.0%
H
2.5
7520
|
L
 -100.0%
H
2.5
27000
|
L
 -100.0%
H
2.5
196400
|
| AIxCrypto Holdings Inc |
|
25.9
|
1.3
|
L
 4.1%
H
1.2
1.3
|
L
 -0.8%
H
1.2
1.3
|
L
 -8.6%
H
1.2
1.5
|
L
 12.3%
H
1.0
1.7
|
L
 -66.1%
H
0.9
8.8
|
L
 -97.3%
H
0.1
63
|
L
 -99.9%
H
0.1
1560
|
L
 -100.0%
H
0.1
468750
|
| Qilian Intl Holding Grp ltd (Class A) |
|
64.2
|
0.3
|
L
H
0.3
0.3
|
L
 10.3%
H
0.3
0.3
|
L
 6.7%
H
0.3
0.5
|
L
 -71.2%
H
0.3
1.2
|
L
 -97.6%
H
0.3
17.2
|
L
 -93.7%
H
0.3
17.2
|
L
 -98.6%
H
0.3
25.0
|
L
H
0.3
110
|
| Quince Therapeutics Inc |
|
22.5
|
1.2
|
L
 -1.7%
H
1.2
1.2
|
L
 4.6%
H
1.1
1.3
|
L
 -6.5%
H
0.8
1.4
|
L
 -8.7%
H
0.8
3.8
|
L
 -88.9%
H
0.8
45.5
|
L
 -92.5%
H
0.8
45.5
|
L
 -99.7%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
1,799.3
|
28.5
|
L
 14.8%
H
27.6
29.5
|
L
 17.9%
H
24
29.5
|
L
 70.5%
H
17.7
29.8
|
L
 82.5%
H
8.7
29.8
|
L
 97.2%
H
8.7
71.5
|
L
 48.4%
H
3.7
71.5
|
L
 -17.9%
H
3.7
71.5
|
L
 137.9%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
10.2
|
5.1
|
L
 2.4%
H
4.7
5.1
|
L
 6.1%
H
4.6
5.2
|
L
 -14.7%
H
4.6
6.7
|
L
 -39.6%
H
4.6
10.8
|
L
 -40.7%
H
4.6
41.8
|
L
 -99.9%
H
4.6
8400
|
L
 -100.0%
H
4.6
3003840
|
L
H
4.6
3003840
|
| Rain Oncology Inc |
|
82.6
|
2.3
|
L
 1.8%
H
2.1
2.4
|
L
 -4.6%
H
2.0
2.5
|
L
 1.3%
H
1.3
2.8
|
L
 -11.7%
H
1.3
3.8
|
L
 -36.9%
H
1.3
8.5
|
L
 108.3%
H
0.8
9.2
|
L
 -88.6%
H
0.8
22.2
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
106.8
|
1.0
|
L
H
0.9
1.0
|
L
 -11.2%
H
0.9
1.0
|
L
 9.2%
H
0.9
1.1
|
L
 -30.7%
H
0.7
1.4
|
L
 69.6%
H
0.4
3.9
|
L
 -77.2%
H
0.4
8.8
|
L
 -99.6%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
2,357.8
|
23.9
|
L
 2.9%
H
23.3
24.1
|
L
 2.4%
H
22.7
24.1
|
L
 -1.0%
H
22.2
27.4
|
L
 2.4%
H
18.3
27.4
|
L
 -29.7%
H
18.3
42.4
|
L
 -50.5%
H
18.3
60.4
|
L
 -76.5%
H
18.3
105.5
|
L
 -65.1%
H
18.3
179.7
|
| Rocket Pharmaceuticals Inc |
|
335.2
|
3.1
|
L
 1.7%
H
3.0
3.1
|
L
 3.7%
H
3.0
3.1
|
L
 -11.8%
H
2.9
4.0
|
L
 -38.7%
H
2.9
5.5
|
L
 22.3%
H
2.4
5.5
|
L
 -85.1%
H
2.2
32.5
|
L
 -92.8%
H
2.2
49.7
|
L
 -91.5%
H
2.2
67.5
|
| Regeneron Pharma |
|
64,452.9
|
614.8
|
L
 -1.1%
H
609.8
624.5
|
L
 -3.8%
H
609.8
648.5
|
L
 -10.4%
H
609.8
730.6
|
L
 -21.4%
H
609.8
794.8
|
L
 25.4%
H
476.5
821.1
|
L
 -15.6%
H
476.5
1211.2
|
L
 22.4%
H
476.5
1211.2
|
L
 55.2%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
717.6
|
8.7
|
L
 85.7%
H
7.7
9.1
|
L
 77.0%
H
4.5
9.1
|
L
 265.1%
H
2.4
9.1
|
L
 13.6%
H
1.5
9.1
|
L
 -3.2%
H
1.5
13.2
|
L
 -53.1%
H
1.5
24.8
|
L
 -77.7%
H
1.5
40.2
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.3
|
1.1
|
L
H
1.1
1.1
|
L
 2.8%
H
1.1
1.1
|
L
 -4.4%
H
0.9
1.2
|
L
 -16.7%
H
0.9
1.4
|
L
 -89.2%
H
0.9
13.8
|
L
 -100.0%
H
0.9
6796.8
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Regencell Bioscience Holdings Ltd |
|
11,818.3
|
23.9
|
L
 -0.9%
H
23.7
24.6
|
L
 -7.4%
H
23.1
27.5
|
L
 -17.4%
H
23.1
32
|
L
 -8.9%
H
20
40
|
L
 3.6%
H
9.4
83.6
|
L
 4093.0%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
6,991.7
|
124.0
|
L
 1.0%
H
121.8
125.6
|
L
 7.7%
H
112
126.7
|
L
 9.6%
H
101.0
131.5
|
L
 -3.7%
H
101.0
141.5
|
L
 5.0%
H
101.0
175.8
|
L
 -28.5%
H
101.0
211.1
|
L
 -32.1%
H
101.0
327.3
|
L
 411.3%
H
21.1
327.3
|
| Regenxbio Inc |
|
362.4
|
7.0
|
L
 1.7%
H
6.8
7.1
|
L
 10.4%
H
6.1
7.1
|
L
 -16.6%
H
5.5
11.4
|
L
 -22.5%
H
5.5
11.4
|
L
 -20.8%
H
5.5
16.2
|
L
 -59.9%
H
5.0
28.8
|
L
 -80.1%
H
5.0
46.5
|
L
 -44.1%
H
5.0
85.1
|
| Rigel Pharma |
|
564.1
|
30.5
|
L
 1.5%
H
29.8
31.2
|
L
 5.1%
H
28.5
31.2
|
L
 4.4%
H
25.5
33.0
|
L
 -12.2%
H
25.0
35
|
L
 58.8%
H
18.1
52.2
|
L
 2125.5%
H
0.7
52.2
|
L
 719.6%
H
0.6
52.2
|
L
 1139.4%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
3,062.1
|
14.1
|
L
 1.1%
H
13.6
14.4
|
L
 3.8%
H
13.3
14.9
|
L
 11.8%
H
11.6
15.5
|
L
 36.9%
H
9.1
17.3
|
L
 368.3%
H
2.9
17.3
|
L
 28.4%
H
1.8
17.3
|
L
 -56.3%
H
1.8
38.6
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
756.3
|
7.2
|
L
 -0.6%
H
7.1
7.3
|
L
 2.4%
H
6.9
7.4
|
L
 -2.2%
H
6.2
8
|
L
 58.1%
H
4.2
8
|
L
 861.3%
H
0.5
8
|
L
 142.8%
H
0.2
8
|
L
 -79.2%
H
0.2
38.7
|
L
 -43.1%
H
0.2
54
|
| TransCode Therapeutics Inc |
|
4.9
|
5.1
|
L
 -2.8%
H
5.1
5.5
|
L
 -17.6%
H
5.0
5.9
|
L
 -38.8%
H
5.0
9.3
|
L
 -46.5%
H
5.0
10.4
|
L
 -24.3%
H
5.0
21.0
|
L
 -100.0%
H
5.0
206606.4
|
L
H
5.0
5174400
|
L
H
5.0
5174400
|
| RenovoRx Inc |
|
41.0
|
0.9
|
L
 -8.1%
H
0.9
1.0
|
L
 3.4%
H
0.8
1.0
|
L
 9.6%
H
0.8
1.0
|
L
 3.4%
H
0.8
1.3
|
L
 -35%
H
0.7
1.5
|
L
 -51.1%
H
0.6
3.3
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
21,570.9
|
30.0
|
L
 0.4%
H
29.7
30.4
|
L
 0.1%
H
29.0
30.4
|
L
 9.0%
H
27.5
32.8
|
L
 3.6%
H
26.0
32.8
|
L
 172.9%
H
10.7
32.8
|
L
 230.7%
H
8.2
32.8
|
L
 204.5%
H
2.5
32.8
|
L
H
2.5
32.8
|
| Royalty Pharma PLC (Class A) |
|
24,717.0
|
55.8
|
L
 2.4%
H
54.3
56.1
|
L
 2.3%
H
53.5
56.1
|
L
 12.7%
H
49.1
56.1
|
L
 20.7%
H
44.7
56.1
|
L
 69.6%
H
32.7
56.1
|
L
 71.5%
H
24.1
56.1
|
L
 39.0%
H
24.1
56.1
|
L
H
24.1
56.5
|
| Revolution Medicines Inc |
|
33,479.7
|
157.5
|
L
 1.8%
H
153.2
158.1
|
L
 3.9%
H
149.1
158.1
|
L
 12.1%
H
138.8
158.1
|
L
 54.4%
H
91.5
158.1
|
L
 299.7%
H
34
158.1
|
L
 529.4%
H
15.5
158.1
|
L
 426.5%
H
14.1
158.1
|
L
H
14.1
158.1
|
| Recursion Pharma Inc (Class A) |
|
1,905.4
|
3.6
|
L
 4.4%
H
3.4
3.7
|
L
 19.3%
H
2.9
3.7
|
L
 8.8%
H
2.8
3.7
|
L
 -2.2%
H
2.8
3.9
|
L
 -14.1%
H
2.8
7.2
|
L
 -59.3%
H
2.8
16.7
|
L
 -86.4%
H
2.8
42.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
6,052.8
|
88.3
|
L
 -5.0%
H
88.0
93.5
|
L
 0.6%
H
87.8
93.5
|
L
 7.6%
H
79.4
99
|
L
 -4.8%
H
74.5
100
|
L
 44.0%
H
60.7
122.2
|
L
 427.3%
H
15.5
122.2
|
L
 350.4%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
317.8
|
3.3
|
L
 0.9%
H
3.2
3.5
|
L
 1.5%
H
3.2
3.5
|
L
 5.8%
H
2.8
3.6
|
L
 2.8%
H
2.3
3.9
|
L
 -19.9%
H
1.1
11.5
|
L
 57.9%
H
0.7
11.5
|
L
 -68.1%
H
0.7
17.4
|
L
 -92.8%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
5.2
|
1
|
L
H
1.0
1.0
|
L
 2.0%
H
1.0
1.1
|
L
 -3.9%
H
0.9
1.1
|
L
 3.1%
H
0.7
1.1
|
L
 -44.1%
H
0.7
3.3
|
L
 -98.2%
H
0.7
82
|
L
 -100.0%
H
0.7
11180
|
L
 -100.0%
H
0.7
16540
|
| SAB Biotherapeutics Inc |
|
275.3
|
3.6
|
L
 0.8%
H
3.5
3.7
|
L
 -7.7%
H
3.5
3.9
|
L
 3.5%
H
3.4
4.6
|
L
 -12.2%
H
3.4
5.2
|
L
 86.5%
H
1.6
6.6
|
L
 300%
H
0.4
6.6
|
L
 -63.7%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
918.4
|
3.3
|
L
 5.4%
H
3.1
3.3
|
L
 7.5%
H
3.0
3.3
|
L
 1.5%
H
2.9
3.8
|
L
 -21.6%
H
2.7
4.3
|
L
 52.1%
H
2.1
6.6
|
L
 -43.1%
H
1.3
12
|
L
 -84.3%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
74.4
|
1.5
|
L
 -0.7%
H
1.5
1.6
|
L
 17.6%
H
1.4
1.6
|
L
 6.9%
H
1.2
1.6
|
L
 -32.5%
H
1.2
2.5
|
L
 -23.4%
H
1.2
5.0
|
L
 -93.2%
H
1.2
42.2
|
L
 -97.1%
H
1.2
146.2
|
L
 -90.5%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
0.4
|
0.3
|
L
 -21.9%
H
0.3
0.3
|
L
 -47.9%
H
0.3
0.5
|
L
 -74.2%
H
0.3
2.3
|
L
 -79.2%
H
0.3
2.3
|
L
 -82.5%
H
0.3
2.4
|
L
 -99.6%
H
0.1
67.0
|
L
 -100.0%
H
0.1
4284
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
62.6
|
8.9
|
L
 23.4%
H
7.4
9.7
|
L
 45.7%
H
5.8
9.7
|
L
 3.0%
H
5.6
12.3
|
L
 8.4%
H
4.2
12.3
|
L
 73.8%
H
4.2
34.3
|
L
 46.6%
H
0.2
34.3
|
L
 -10.1%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
7.0
|
0.7
|
L
 -5.4%
H
0.7
0.8
|
L
 -4.1%
H
0.7
0.8
|
L
 -24.7%
H
0.6
1.0
|
L
 -6.7%
H
0.6
1.1
|
L
 -20.5%
H
0.6
1.3
|
L
 -72.2%
H
0.6
3.9
|
L
 -92.7%
H
0.6
10.3
|
L
 -98.1%
H
0.6
55.1
|
| Seer Inc (Class A) |
|
102.8
|
1.9
|
L
 -3.1%
H
1.9
1.9
|
L
 4.5%
H
1.8
1.9
|
L
 -0.5%
H
1.7
2.1
|
L
 8.7%
H
1.7
2.1
|
L
 -2.6%
H
1.7
2.4
|
L
 -49.9%
H
1.5
5.7
|
L
 -93.7%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,167.6
|
7.5
|
L
 4.6%
H
6.9
7.6
|
L
 11.7%
H
6.0
7.6
|
L
 16.5%
H
6.0
9.3
|
L
 -0.7%
H
5.6
9.3
|
L
 -21.1%
H
5.6
15.6
|
L
 -26.5%
H
5.6
15.6
|
L
 -26.5%
H
5.6
15.6
|
L
 -26.5%
H
5.6
15.6
|
| Shuttle Pharma Holdings Inc |
|
3.0
|
0.5
|
L
 -3.7%
H
0.5
0.6
|
L
 -10.3%
H
0.5
0.6
|
L
 -48%
H
0.5
1.1
|
L
 -48%
H
0.5
1.2
|
L
 -88.1%
H
0.5
6.2
|
L
 -99.8%
H
0.5
254
|
L
H
0.5
25252
|
L
H
0.5
25252
|
| SIGA Tech Inc |
|
335.7
|
4.7
|
L
 -1.7%
H
4.7
4.8
|
L
H
4.7
4.8
|
L
 3.3%
H
4.1
4.9
|
L
 -27.7%
H
4.1
6.6
|
L
 -21.7%
H
4.1
9.6
|
L
 -16.0%
H
4.1
12.8
|
L
 -33.6%
H
4.1
27.0
|
L
 524%
H
0.7
27.0
|
| SILO Pharma Inc |
|
7.0
|
0.4
|
L
 2.4%
H
0.4
0.5
|
L
 10.3%
H
0.4
0.5
|
L
 -4.4%
H
0.3
0.5
|
L
 16.2%
H
0.3
0.7
|
L
 -2.3%
H
0.2
1.0
|
L
 -79.7%
H
0.2
4.5
|
L
 -96.5%
H
0.2
496
|
L
 -99.1%
H
0.2
496
|
| Solid Biosciences Inc |
|
722.6
|
7.3
|
L
 3.8%
H
7.0
7.5
|
L
 10.9%
H
6.7
7.5
|
L
 4.1%
H
6
7.9
|
L
 18.2%
H
5.5
8.9
|
L
 128.7%
H
3.1
8.9
|
L
 19.5%
H
1.8
15.1
|
L
 -87.1%
H
1.8
73.7
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
241.4
|
73.9
|
L
 -1.9%
H
72.5
81.5
|
L
 -3.7%
H
67.5
81.5
|
L
 3.5%
H
62.5
81.5
|
L
 -19.4%
H
61.9
98.0
|
L
 924.4%
H
6.8
98.0
|
L
 2072.4%
H
0.3
98.0
|
L
 615.0%
H
0.3
98.0
|
L
H
0.3
98.0
|
| SELLAS Life Sciences Grp Inc |
|
1,732.0
|
9.3
|
L
 1.4%
H
8.6
9.5
|
L
 19.7%
H
7.4
9.5
|
L
 99.4%
H
4.7
9.5
|
L
 88.8%
H
4.0
9.5
|
L
 444.4%
H
1.4
9.5
|
L
 438.2%
H
0.5
9.5
|
L
 -22.2%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Summit Therapeutics Inc |
|
13,613.9
|
17.5
|
L
 0.8%
H
17.4
18.5
|
L
 5.5%
H
15.9
18.5
|
L
 -15.8%
H
15.1
22.4
|
L
 5.7%
H
14.6
29.2
|
L
 -3.7%
H
13.8
31.0
|
L
 1024.4%
H
1.5
36.9
|
L
 124.3%
H
0.7
36.9
|
L
 109.3%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,735.9
|
19.6
|
L
 -0.8%
H
19.4
19.9
|
L
 -1.8%
H
19.3
20.4
|
L
 -5.0%
H
19
22.7
|
L
 -9.8%
H
19
25.6
|
L
 85.9%
H
8.6
25.6
|
L
 -1.6%
H
8.6
25.6
|
L
 6.6%
H
8.6
29.9
|
L
 41.0%
H
3.4
29.9
|
| Soligenix Inc |
|
13.5
|
0.9
|
L
 -6.2%
H
0.9
1
|
L
 133.3%
H
0.4
1.1
|
L
 167.7%
H
0.3
1.1
|
L
 -22.9%
H
0.3
1.4
|
L
 -51.9%
H
0.3
6.2
|
L
 -92.2%
H
0.3
85.3
|
L
 -99.6%
H
0.3
321.6
|
L
 -99.9%
H
0.3
2136.0
|
| Sonoma Pharma Inc |
|
4.0
|
1.1
|
L
 2.7%
H
1.1
1.2
|
L
 3.6%
H
1.1
1.2
|
L
 7.6%
H
1
1.3
|
L
 -60.7%
H
0.9
3.1
|
L
 -67.2%
H
0.9
6.9
|
L
 20%
H
0.1
6.9
|
L
 -85.1%
H
0.1
13.4
|
L
 -97.4%
H
0.1
74.2
|
| Synaptogenix Inc |
|
31.4
|
4.2
|
L
 -4.1%
H
4
4.5
|
L
 -7.3%
H
4
4.8
|
L
 -13.0%
H
4
6.9
|
L
 7.4%
H
3.7
7.2
|
L
 66.7%
H
2.4
12.0
|
L
 412.2%
H
0.1
12.0
|
L
 -42.9%
H
0.1
14.5
|
L
H
0.1
14.5
|
| Sensei Biotherapeutics Inc |
|
28.4
|
21.1
|
L
 20.2%
H
19.0
21.5
|
L
 18.8%
H
15.5
21.5
|
L
 -25.3%
H
15.5
33
|
L
 -30.7%
H
15.5
36.1
|
L
 250%
H
5.6
36.8
|
L
 -29.5%
H
5
38.8
|
L
 -91.5%
H
5
260
|
L
H
5
530
|
| Senti Biosciences Inc |
|
29.6
|
1.0
|
L
 -5%
H
1.0
1.0
|
L
 -4.0%
H
1.0
1.0
|
L
 -3.1%
H
0.9
1.1
|
L
 1.1%
H
0.8
1.2
|
L
 -69.8%
H
0.8
3.9
|
L
 -90%
H
0.8
16.9
|
L
 -5%
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
141.1
|
51.3
|
L
 4.2%
H
47.5
51.9
|
L
 0.4%
H
47.5
54.1
|
L
 -7.7%
H
47.5
60.3
|
L
 -6.7%
H
47.5
80
|
L
 483.3%
H
7.3
240
|
L
 -71.5%
H
4.3
446.3
|
L
 -95.2%
H
4.3
1108.5
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
5.6
|
9.8
|
L
 -7.0%
H
8.2
10.1
|
L
 129.7%
H
4.3
15.7
|
L
 8.6%
H
4
15.7
|
L
 96.2%
H
3.0
15.7
|
L
 -83.5%
H
3.0
80.1
|
L
 -99.7%
H
3.0
4471.7
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| Spero Therapeutics Inc |
|
163.9
|
2.8
|
L
 -2.4%
H
2.8
2.9
|
L
 2.5%
H
2.8
3.1
|
L
 11.9%
H
2.4
3.1
|
L
 30.4%
H
2.1
3.1
|
L
 13.2%
H
1.8
3.2
|
L
 59.9%
H
0.5
3.2
|
L
 -80.5%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
900.7
|
9.1
|
L
 -3.5%
H
9.0
9.9
|
L
 14.2%
H
7.9
9.9
|
L
 15.7%
H
7.0
9.9
|
L
 -2.3%
H
7.0
9.9
|
L
 -37.1%
H
6.7
18.9
|
L
 31.1%
H
2.6
18.9
|
L
 -67.1%
H
2.6
35.6
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
75.2
|
1.5
|
L
 7.9%
H
1.3
1.6
|
L
 5.6%
H
1.3
1.6
|
L
 -14.8%
H
1.2
1.8
|
L
 -52.4%
H
1.2
4.6
|
L
 -44.2%
H
1.2
5.3
|
L
 212.5%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,886.6
|
17.9
|
L
 3.3%
H
17.4
18.0
|
L
 6.4%
H
16.4
18.0
|
L
 -13.6%
H
16.4
23.5
|
L
 6.6%
H
15.5
23.9
|
L
 -52.5%
H
10.4
43.9
|
L
 -85.7%
H
10.4
173.3
|
L
 -76.4%
H
10.4
173.3
|
L
 -15.7%
H
10.4
181.8
|
| Scholar Rock Holding Corp |
|
5,907.5
|
49.3
|
L
 -1.0%
H
48.9
50.2
|
L
 2.4%
H
47.8
52.2
|
L
 6.5%
H
45
52.2
|
L
 11.4%
H
38.8
52.2
|
L
 69.9%
H
27.1
52.2
|
L
 751.5%
H
5.6
52.2
|
L
 83.5%
H
4.3
52.2
|
L
H
4.3
70
|
| Surrozen Inc |
|
304.3
|
26.2
|
L
 0.2%
H
24.3
26.9
|
L
 -0.6%
H
24.3
27.1
|
L
 -17.0%
H
24.3
35
|
L
 -5.7%
H
23.4
35
|
L
 208.7%
H
7.8
35
|
L
 3932.3%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,925.1
|
30.9
|
L
 -2.2%
H
30.7
31.9
|
L
 5.4%
H
29.4
32.4
|
L
 -4.7%
H
28.0
35.2
|
L
 -15.1%
H
28.0
40.2
|
L
 224%
H
9.5
40.2
|
L
 184.9%
H
3.4
40.2
|
L
 -22.1%
H
3.4
41.6
|
L
H
3.4
71.6
|
| Sutro Biopharma Inc |
|
484.4
|
29.2
|
L
 -1.4%
H
28.4
29.7
|
L
 14.3%
H
25.1
30.6
|
L
 -17.4%
H
25.1
43.9
|
L
 42.8%
H
18.7
43.9
|
L
 225.5%
H
6.7
43.9
|
L
 -36.6%
H
5.2
61.3
|
L
 -84.3%
H
5.2
237
|
L
H
5.2
283
|
| Shattuck Labs Inc |
|
456.2
|
6.0
|
L
 -0.3%
H
5.7
6.1
|
L
 -2.5%
H
5.7
6.3
|
L
 -16.1%
H
5.7
7.8
|
L
 51.8%
H
3.8
8.3
|
L
 489.1%
H
0.7
8.3
|
L
 107.3%
H
0.7
11.8
|
L
 -78.1%
H
0.7
31.2
|
L
H
0.7
60.5
|
| Supernus Pharma Inc |
|
2,680.3
|
46.2
|
L
 -1.4%
H
46.0
47.2
|
L
 -4.2%
H
45.9
48.7
|
L
 -4.9%
H
45.9
53.0
|
L
 -15.6%
H
45.9
56.5
|
L
 45.7%
H
30.8
59.7
|
L
 38.8%
H
22
59.7
|
L
 54.7%
H
22
59.7
|
L
 141.1%
H
13.1
61.3
|
| Savara Inc |
|
1,065.6
|
5.2
|
L
 2.2%
H
5.0
5.3
|
L
 3.6%
H
5.0
5.4
|
L
 7.2%
H
4.7
5.4
|
L
 -13.6%
H
4.7
6.2
|
L
 128.1%
H
2.0
7
|
L
 100%
H
1.9
7
|
L
 188.9%
H
1.0
7
|
L
 -77.9%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
7.4
|
1.7
|
L
 7.1%
H
1.6
1.7
|
L
 0.6%
H
1.4
1.7
|
L
 -18.5%
H
1.4
2.1
|
L
 -26.8%
H
1.3
2.6
|
L
 20.1%
H
0.0
7.0
|
L
 -67.3%
H
0.0
9.4
|
L
 -94.8%
H
0.0
57
|
L
H
0.0
2335
|
| 60 Degrees Pharma Inc |
|
4.0
|
1.5
|
L
H
1.5
1.5
|
L
 0.7%
H
1.4
1.6
|
L
 -5.1%
H
1.4
1.7
|
L
 -52.1%
H
1.3
3.6
|
L
 -85.6%
H
1.3
14.7
|
L
H
1.3
2076
|
L
H
1.3
2076
|
L
H
1.3
2076
|
| Sanofi (ADR) |
|
104,535.9
|
43.7
|
L
 -1.4%
H
43.6
44.1
|
L
 -1.4%
H
43.6
45.0
|
L
 -5.1%
H
42.3
47.0
|
L
 -10.3%
H
42.3
48.6
|
L
 -11.6%
H
42.3
52.7
|
L
 -13.4%
H
42.3
60.1
|
L
 -18.3%
H
36.9
60.1
|
L
 5.8%
H
36.8
60.1
|